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Peri-implant fibrosis poses a substantial setback in regenerative medicine and effective 
fibrosis treatment remains an unmet clinical need. Our group has firstly described the 
potential anti-fibrotic effects of suberoylanilide hydroxamic acid (SAHA). When 
administered in the presence of profibrotic factor transforming growth factor (TGF)-β, 
SAHA abrogated TGFβ1-effects by preventing fibroblast transition into collagen I 
overproducing and α-SMA expressing myofibroblasts. However, SAHA no longer 
exerted anti-fibrotic effects when myofibroblasts were treated with TGFβ1 24h prior to 
SAHA. Many hormones and growth factors impact cells in pulses, yet current protocols 
employ continuous TGFβ1 exposure to cells. We therefore evaluated the effects of 
pulsatile TGFβ1 treatment in the creation and maintenance of the myofibroblast 
phenotype to better assess SAHA’s anti-fibrotic potential in a physiologically relevant 
setting. We demonstrated that a single 0.5h TGFβ1 pulse was sufficient to effect long-
term changes towards the myofibroblast phenotype, potentiated by a second pulse 24h 
later. We further established that decellularized ECM deposited under TGFβ1 pulses 
induced myofibroblast features in previously untreated fibroblasts.  Revisiting SAHA’s 
effects in TGFβ1 pulses we demonstrated, for the first time the normalization of TGFβ1-
effects and thereby reconfirmed SAHA’s anti-fibrotic potential. As SAHA leads to the 
hyperacetylation of α-tubulin, a cytoskeletal component in fibroblasts, we therefore 
investigated mechanical and locomotional properties of SAHA-treated myofibroblasts as 
this may reveal an additional therapeutic facet. We presented novel evidence of 
compromised motility, but not contractility, in SAHA-treated myofibroblasts. Our findings 
contribute to the current understanding of fibroblast induction, maintenance and the use 
of an FDA-approved agent to curb fibrosis. Because SAHA is already in clinical use, the 
findings derived from this thesis can be faster translated towards clinical therapy.   
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Chapter 1  
Overview of research project 
This chapter introduces the rationale and core hypotheses of the project. Aims and 
objectives are outlined, along with the strategy and methods to achieve them. 
 
1.1 Background 
Wound healing is a physiological response of tissue upon injury. However, when this response 
is perpetuated with events such as chronic inflammation, fibrosis ensues. Fibrosis comes in 
many forms, ranging from simple cosmetics scars, disfiguring impairments and peri-implant 
fibrosis – a bottleneck in tissue engineering that often leads to implant failure and/or loss of 
organ function, a consequence of the host’s natural response in an attempt to destroy or 
phagocytose the implant. Hence, there is an urgent clinical need to: i) understand the regulation 
of fibrosis induction and maintenance; and ii) utilize modulators to reverse or curb fibrosis.  
The hypotheses behind this project are based on the following observations: 
 In an indication discovery approach, Wang et al. firstly observed the anti-fibrotic effects of 
the epigenetic drug – suberoylanilide hydroxamic acid (SAHA). SAHA is a FDA-approved, 
broadband histone deacetylase (HDAC) inhibitor currently in clinical use for T cell lymphoma. 
When administered in conjunction with profibrotic cytokine transforming growth factor beta-1 
(TGFβ1), SAHA abrogated TGFβ1-effects in normal and pathological fibroblasts lines by 
preventing differentiation into alpha-smooth muscle actin (α-SMA) positive myofibroblasts 
and normalized collagen deposition back to normal or subnormal levels [Wang et al. 2009]. 
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However, when fibroblasts were treated with TGFβ1 24h before SAHA, SAHA was no longer 
able to exert anti-fibrotic effects (own observations). 
 We therefore, were forced to relook current in vitro fibrosis setups. Current in vitro fibrotic 
studies traditionally employ TGFβ1 as a culture media additive for four days to generate 
myofibroblasts [Hinz et al. 2001]. However, a time course study of active TGFβ1 generation 
in an incisional wound repair animal model reported pulsatile in vivo TGFβ1 regulation [Yang 
et al. 1999]. 
 Intrigued by the findings of the newly developed in vitro model, a study into the mechanistic 
events of TGFβ1 pulsatile regulation was conducted. 
The hypothesis behind this project was: 
Simulating prevailing in vivo cytokine regulation will lead to the development of 
physiologically relevant in vitro model, better suited for (SAHA-based) anti-fibrotic agent 
characterization 
1.2 Aims and Objectives 
In order to address the hypothesis, this project was divided into the following aims: 
Aim #1: Characterize the effects of TGFβ1 pulses to develop a physiologically relevant in vitro 
fibrotic model  
For effective anti-fibrotic compound screening, an in vitro model that accurately recapitulated 
physiological in vivo cytokine regulation was required. An in-depth characterization of two 
wound healing models: a single-pulse model – which reflects a normal wound healing situation; 
and the multiple pulses model – simulating a wound healing situation leading to fibrosis, was 
presented.  
Aim #2: To investigate “memory” in TGFβ1 pulses 
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Epigenetics and cell – ECM communication play a key role in fibrogenesis. We therefore, 
investigated autocrine TGFβ1 production, epigenetics mechanisms and the influence of TGFβ1-
pulsed ECM on the fibroblast phenotype. Further, we investigated the effects of the normal 
fibroblast ECM on the myofibroblast phenotype. 
Aim #3: To study the potential of SAHA as an anti-fibrotic drug 
SAHA has recently demonstrated anti-fibrotic potential. However, there was still the need to 
better understand SAHA’s effects in curbing fibrosis before moving into animal studies. As 
SAHA is an FDA-approved cancer drug in clinical use, data obtained from this study can be 
moved into the preclinical animal models with good reasons and data from in vivo studies can 
be faster translated towards clinical therapy. 
a) Assess SAHA’s effects on TGFβ1-pulsed myofibroblast formation 
Prior treatment with TGFβ1 before SAHA treatment sets a boundary for SAHA’s anti-fibrotic 
potential. Several permutations of SAHA treatment in conjunction with TGFβ1 pulsing were 
assessed. 
b) Elucidate SAHA’s effects on locomotion, contractility and apoptosis in myofibroblasts 
SAHA hyperacetylated α-tubulin, a cytoskeletal component in fibroblasts and suggested that 
HDAC6, a microtubule associated deacetylase was inhibited. However, SAHA’s effects on the 
mechanical properties of myofibroblasts remains unknown, and results derived from studying 
mechanical properties in SAHA-treated myofibroblasts may reveal an additional therapeutic 
facet towards anti-fibrosis treatment. 
 1.3 Research Strategy 
Aim #1: Development of a physiologically relevant in vitro fibrotic model  
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To recapitulate and assess in vivo TGFβ1 regulation in vitro, the following models were studied: 
 Single TGFβ1 pulse: 3 time-points were assessed – 0.5h, 4h and 48h of TGFβ1 treatment, 
with cytokine removal thereafter 
 Multiple TGFβ1 pulse(s): We assessed the effects of 0.5h (2 x 0.5h) and 4h (2 x 4h) pulses, 
with cytokine removal in between, over 2 consecutive days 
 Conventional TGFβ1 pulse: Current protocols expose cells to 4 days of TGFβ1 treatment 
and this timeframe  was chosen to simulate current in vitro experimental setups  
Cultures were maintained for a further 14 days in 0.5% FBS DMEM, with endpoint analysis at 
days 1, 7 and 14 post-treatment. Readout parameters included the classic markers of 
myofibroblasts: α-SMA; collagen I production; and the transcription of selected fibrogenic genes 
– α-SMA (ACTA2), Frizzled 8 (FZD8), NADPH-oxidase 4 (NOX4) and Tetraspanin 2 (TSPAN2).  
Aim #2: To investigate “memory” in TGFβ1 pulses 
Mechanistic studies to explain the long-term effects of TGFβ1 pulse(s) were conducted. Briefly, 
TGFβ1 levels in the supernatant were measured using an enzyme-linked immunosorbent assay 
(ELISA). Acetylation and DNA methylation investigations were performed. To investigating cell – 
ECM communication, the effect of TGFβ1-pulsed decellularized ECM on the phenotype of 
untreated fibroblasts was assessed. The influence of fibroblast ECM on myofibroblasts 




Aim #3: To study the potential of SAHA as an anti-fibrotic drug 
a) Assess SAHA treatment on TGFβ1-pulsed myofibroblast formation 
Focusing on the 4h and 2 x 4h TGFβ1 pulse(s), the efficacy of SAHA on reducing and/or 
curbing TGFβ1-pulsed myofibroblast formation was studied thus: 
 SAHA pre-treatment on TGFβ1 pulse(s): Cells were treated with SAHA for 24h before 
exposure to either 4h or 2 x 4h TGFβ1 pulse(s), with cytokine removal thereafter. 
 SAHA post-treatment on TGFβ1 pulse(s): Cells were treated with either 4h or 2 x 4h TGFβ1 
pulse(s), followed by 24h of SAHA treatment and removal thereafter. 
 SAHA pre-treatment – TGFβ1 pulse(s) – SAHA post-treatment: Cells were exposed to 24h 
of SAHA treatment followed by TGFβ1 pulse(s). Cells were immediately treated with SAHA 
for 24h and removed thereafter. 
Cultures were maintained for a further 7 days in 0.5% FBS DMEM with endpoint analysis at 
days 1 and 7 post-treatment. Readout parameters included the classic markers of 
myofibroblasts: α-SMA and collagen I production. 
b) Elucidate SAHA’s effects on locomotion, contractility and apoptosis in myofibroblasts 
 Motility of the cells using a scratch assay: Cultures were treated with or without TGFβ1 to 
induce myofibroblast formation. Thereafter, cytokine-containing media was removed and 
cells were treated with or without SAHA and maintained for a further 3 days. Readout 
parameters at selected time-points included live cell analysis of migration into scratch area. 
 Assessment of the contractile ability of cells in a collagen gel: Using a commercial collagen 
contraction assay, cultures were treated with or without TGFβ1 treatment to induce 
myofibroblast formation. Thereafter, cytokine containing media was removed and cultures 
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treated with or without SAHA and maintained for a further 3 days. Readout parameters at 
various time-points included live cell analysis of contraction.  
 Apoptosis induction in SAHA-treated cells: Cultures were treated with or without 4 days of 
TGFβ1. Cytokine containing media was removed and replaced with or without SAHA. 
Cultures were maintained for a further 4 days with endpoint analysis at days 1, 2 and 4. 





Literature Review: The etiology of fibrosis 
This chapter contains an in-depth review of fibrogenesis, its progression and the 
clinical burden fibrosis poses today and describes the rationale behind the project . 
Cell – ECM interactions and epigenetic modifications focusing on fibrogenesis are 
discussed. 
 
2.1 Overview of Fibrosis 
Wound healing can take place in every part of the body and consists of a cascade of tightly-
regulated events to enable the body to repair and regain function. Upon healing, the original 
wound is replaced by connective tissue. This is commonly known as a scar.   
A scar is, in general, not harmful to the body and represents a quick repair system to regain 
function. However, when there is an imbalance in the wound healing process, such as the 
perpetuation of tissue injury, chronic inflammation, excessive consumption of alcohol, chemo- or 
radiotherapy, and/or other toxins, fibrosis ensues. Histopathologically, fibrosis is characterized 
by the excessive accumulation and reduced remodeling of the ECM. It involves the 
misregulation of collagen I and the hyperproliferation of fibroblasts / myofibroblasts. The 
response to tissue insult commences at the point of injury, and the initiation of fibrosis ranges 
from weeks to months.  
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2.1.1 The global burden of fibrosis 
Fibrosis poses a substantial disease burden, in South-East Asia as well as globally. 
Fibroproliferative diseases affect almost every organ. For example, there are at least 5 million 
cases worldwide of idiopathic lung fibrosis (IPF). The mortality rate for IPF is 50% after 2 to 3 
years post diagnosis and at least 45,000 individuals in the US die from this disease every year 
[Meltzer et al. 2008, Mason 1999]. Scleroderma/systemic sclerosis (Ssc) displays much 
variation in severity between patients, ranging from cutaneous regions to internal organs. 
Patients with severe, rapidly progressive SSc have been estimated to have only a 50% chance 
of five-year survival [Furst et al. 2012]. Viral hepatitis B and C (HPB/C) are rampant and 
continue to pose significant clinical risks. For hepatitis C alone, the global prevalence is 
estimated at 170 million [Pol et al. 2012]. End stage liver disease leading to liver transplantation, 
complications of chronic infections and liver fibrosis/cirrhosis are similarly common [WHO, 2004]. 
Keloid and hypertrophic (less severe) complications are common within scar tissue. Other 
occurrences of fibrosis include endomyocardial / old myocardial fibrosis (heart), myelofibrosis 
(bone marrow) and Crohn’s disease (intestine), all pathological conditions which highlight the 
unmet clinical need for an effective anti-fibrotic therapy.  
2.1.2 Peri-implant fibrosis: A bottleneck in regenerative medicine 
The objective of tissue engineering is the successful incorporation of implanted biomaterials, 
cells or whole organs into the body [Ratner B.D 2002]. An unaddressed bottleneck in this 
discipline is foreign body reaction or peri-implant fibrosis, a consequence of the host’s natural 
response to destroy or phagocytose the implant [Anderson et al. 2008]. Host responses to an 
implant follow a cascade of events similar to, but ultimately divergent from wound healing. If the 
host is unable to break down the implant, the implant will eventually be encapsulated within 
fibrous tissue with minimal vascularisation, effectively isolating it from surrounding tissues. 
Evidence of fibrous encapsulation around implanted biomedical devices [Tang et al. 1995], 
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biosensors [Henninger et al. 2007], aortic valve replacements [O'Keefe et al, 2011; Cicha et al. 
2011], synthetic prosthetics [Harrell et al. 2006, Dolce et al. 2010] and breast implants [Zeplin et 
al. 2010; Bartsich et al. 2011] have been well documented. In summary, peri-implant fibrosis 
impairs the function of biomaterials and biomedical devices, rendering many unsuccessful 
preliminary efforts to engineer biomaterials safe for implantation. 
2.2 Wound healing and fibrosis: Focus on foreign body reaction 
Wound healing is a highly conserved physiological process designed to be nature’s “quick fix” 
for the repair of injured tissue. It has not evolved to serve aesthetics, but rather to rapidly 
replace tissue without regard for the restoration of normal morphology and functionality. This 
mechanism has evolved to reduce the duration of exposure to the environment and the risks of 
subsequent bacterial infections. The process often compromises tissue architectural integrity, 
resulting in inadequate restoration. An overview of fibrous encapsulation after foreign body 
reaction is illustrated in Figure 1. 
 
Figure 1. Different stages of foreign body reaction leading to collagenous encapsulation 
surrounding the implant. Adapted from [Ratner B.D 2002]. 
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Host reactions upon implantation can be classically divided into hemostasis, acute and chronic 
inflammatory, proliferative and remodeling phases leading to fibrous capsule formation. In this 
thesis however, an alternative model by Nguyen et al. will be used as a reference [Nguyen et al. 
2009]. This model describes a clearer, more delineated process, where wound healing is 






1 Within minutes – 
24h 
Early   Platelet activation and aggregation 
 Initiation of inflammation 
 Endothelial cell migration 
2 Day 1 - 2  Cellular  Infiltration of macrophages and 
inflammatory components 
3 Within hours – day 
1 – 2  
Cellular  Re-epithelization 
 Damaged ECM breakdown 
4 Day 4 – 14  Cellular  Fibroblast – myofibroblast differentiation 
5 Day 4 – 14 Cellular  Endothelial cell migration and 
angiogenesis 
6 Day 4 – months/ 
years 
Cellular  Remodeling of scar tissue 
 Maturation of tissue 
Table 1. Duration of fibrosis formation and progression surrounding an implant.  In this model, 
wound healing is delineated into the early and cellular phases. Summarized from [Nguyen et al. 2009]. 
2.2.1 Early phase: Hemostasis and formation of the fibrin clot 
The immediate response (within minutes) of a host to a foreign object is a barrage of chemical 
and mechanical signals, resulting in the formation of a provisional ECM (the hemostatic plug). 
The damage to surrounding blood vessels triggers a response activating several “stress signals” 
for platelet activation and aggregation, which in turn establish hemostasis. Platelets 
(thrombocytes) are the most abundant cell source recruited as they release a reservoir of 
molecules that become involved in the coagulation cascade. Activated platelets initiate 
inflammation by releasing chemotactic agents such as metalloproteinases, tissue factor, 
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serotonin, bradykinin, histamine, prostaglandins, prostacyclin and thromboxane, all of which are 
involved in the formation of hemostatic plug. Platelets also release a panoply of growth factors, 
including platelet-derived growth factor (PDGF) and TGFβ1, which in turn initiate the chemotaxis 
of neutrophils, fibroblasts, macrophages and endothelial cells from surrounding regions [Nurden 
et al. 2011]. Platelets also express glycoproteins that allow the conversion and collective 
accumulation of fibrinogen-to-fibrin at the implant site. This forms a fibrin clot of provisional ECM 
which then serves as a “scaffold” to provide support for subsequent epithelial migration and 
cellular infiltration. Thus, the provisional ECM forms the structural and mechanical basis for 
subsequent cellular activity by providing a source of cues that controls the complex process of 
wound healing.  
2.2.2 Cellular phase 
In the cellular phase, different cell types work in synergy to restore a rudimentary degree of 
structural integrity to the implant region. The various components that are individually addressed 
here do not occur in series, but instead partially overlap in time. 
2.2.2.1 Inflammation and macrophages infiltration 
After formation of the provisional ECM, immune cells infiltrate the injury site and mount an 
inflammatory response within minutes to days. Short-lived, blood-derived polymorphonuclear 
neutrophils (PMNs) and monocytes, the latter subsequently activated to become macrophages, 
rapidly migrate into injured area. Together, macrophages and neutrophils remove foreign 
microorganisms, bacteria, damaged ECM components and other non-essential materials 
[Mahdavian-Delavary et al. 2011].  It is also interesting to note that multiple aspects of the 
inflammatory response are in part governed by the biomaterial-dependent behavior of PMNs. 
Various responses of PMNs have been observed on several biomaterials [Gemell et al. 1996, 
Chang et al. 1999, Rosenson-Schloss et al. 2002, Tan et al. 2002] and it has been established 
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that surface material chemistry, size and shape greatly influences the behavior of PMNs in 
response to an implant.  Mononuclear leukocytes such as monocyte-derived macrophages and 
lymphocytes are also involved in this phase of wound healing. These cells play a role in 
neovascularization and the development of connective tissue. Recently, a unique population of 
monoculear leukocytes known as fibrocytes, or bone-marrow derived progenitors has been 
described. Circulating fibrocytes make up less than 1% of the circulating leukocyte population 
and have been documented to assist in the coordination of the inflammatory and reparative 
stages of wound healing [Keeley et al. 2010]. Fibrocytes are recruited early in the wound 
healing phase, and have the ability to take on an antigen-presenting role, thereby producing a 
barrage of signaling molecules. Furthermore, fibrocytes have the ability to secrete collagen I 
and ECM metalloproteinases (MMPs), proteins which greatly contribute to ECM remodeling 
[Grieb et al. 2011]. Although not fully elucidated, there is speculation that fibrocytes may be 
precursors to fibroblasts and myofibroblasts [Abe R. 2001, Schmidt et al. 2003, Ekert et al. 
2011]. 
Macrophages also play a critical role by releasing pro-fibrotic cytokines – PDGF, vascular 
endothelial growth factor (VEGF), fibroblast growth factors (FGFs) and TGFβ1 in bid to promote 
the migration, proliferation and differentiation of fibroblasts and endothelial cells. Macrophages 
are essential for the wound healing process, and the inhibition of macrophage function may lead 
to compromised inflammatory response, markedly impaired vascularization and defective 
wound healing [van Amerongen et al. 2007, Sakurai et al. 2003].  
2.2.2.2 Re-epithelization 
The process of re-epithelization (that occurs within hours and lasts for a few days) commences 
with the migration of epidermal cells. Basal keratinocytes from surrounding areas (wound edge 
and surrounding dermal appendages) are the main cell type responsible for re-epithelization. 
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Keratinocytes first migrate without proliferating, and when at the injury site, proliferate, a 
process which continues until the integrity of the epidermis has been attained. There are several 
reports that migration over the wound site is stimulated by such factors as lack of contact 
inhibition, hypoxia [O’Toole et al. 1987], chymase (chymotrypsin-like serine protease 
predominantly produced by mast cells) [Firth et al. 2008] and nitric oxide [Witte et al. 2002]. This 
process is mediated by cytokines such as epidermal growth factor (EGF), secreted by platelets 
[Wells et al. 1999], and TGFβ1, secreted by keratinocytes, macrophages and platelets. EGF 
and TGFβ1 permit cell detachment and subsequent migration towards the injury site. Epidermal 
cells also express several forms of the transmembrane receptor protein, integrin, which relocate 
over actin filaments within the cytoskeleton to serve as attachment anchors to the ECM during 
migration. Integrins allow cells to interact with a variety of ECM proteins, including fibronectin 
(FN), and binds to other ECM components such as collagens, heparan sulfate, fibrin [Pankov et 
al. 2002], and vitronectin (which promotes cell adhesion and spreading) [Preissner et al. 1998]. 
This process is also mediated by the secretion of zymogens and enzymes which assist in the 
removal of fibrin clots and damaged ECM proteins through the secretion serine protease, 
plasmin and collagenases. Plasminogen (zymogen) is activated by tissue plasminogen activator 
and urokinase upon binding to clots [Silverstein et al. 1984].  
The re-epithelization process is also characterized by the gradual shift from the generalized 
secretion of pro-inflammatory mediators towards formation of a basement membrane and 
synthesis of granulation tissue. 
2.2.2.3 Fibroblast – myofibroblast differentiation 
Approximately 4 days post-implantation (when the inflammatory period is ending), fibroblasts 
invade the wound site and proliferate rapidly. A fibroblast’s chief duty is to secrete collagen, and 
the large increase in the fibroblast population results in the abundant production and 
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accumulation of collagen in the ECM, a process mediated by TGFβ1 [Desmoulière et al. 1993, 
Kottler et al. 2004] and PDGF in the microenvironment. There are two major aspects of the 
wound healing in this phase – collagen deposition and contraction. Collagen fibrils are the main 
component of connective tissues, and form the basis of structural integrity in the wound bed. As 
the provisional ECM does not confer much resistance to the wound bed, it becomes essential 
that collagen is laid down to provide strength and support as the wound closes. Also, 
collageneous ECM allows the attachment of cells involved in the processes of angiogenesis, 
inflammation and tissue reconstruction to attach, grow and differentiate [Ruszczak et al. 2003]. 
To date, 28 members of the collagen family have been identified [Gelse et al. 2003], with 
collagens type I, III and IV being the most essential ones for wound healing. Immediately post-
injury, collagens type III and IV (together with FN) are the proteins providing the predominant 
tensile strength until the stronger type I collagens replace them at later stages. The other aspect 
of wound healing is wound contraction, regulated by a specific cell type known as the 
myofibroblast. Upon stimulation by TGFβ1, fibroblasts differentiate into myofibroblasts. Besides 
fibroblasts, myofibroblasts can also originate from other sources, including hepatic stellate cells 
(HSCs) [Sato et al. 2003], epithelial or endothelial cells which undergo epithelial or endothelial – 
mesenchymal transition (EMT) as in renal fibrosis [Hertig et al. 2010, Fragiadaki et al. 2011], 
and fibrocytes [Ogawa et al. 2006]. Classic markers of the myofibroblasts include elevated 
collagen I production, the expression of the contractile cytoskeletal protein α-SMA, and 
filamentous actin (F-actin) [Hinz et al. 2001]. Myofibroblasts however, are distinct from smooth 
muscle cells, despite both cell types expressing α-SMA as a key marker.  Recent evidence has 
demonstrated distinct transcriptional control mechanisms regulating the expression of α-SMA 
[Gan et al. 2007], and these two cell types can be considered as distinct. The population of 
myofibroblasts in the wound area increases at approximately one week post-wounding and lasts 
for several weeks, even after the wound is completely re-epithelized [Stadelmann et al. 1998]. 
Contraction is mediated by several cellular elements, including integrins, which enable cells to 
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sense mechanical perturbations and transmit intracellular stress to their environment [Wipff et al. 
2008]. Other mediators of contraction include integrin ligand proteins such as FN, vitronectin 
and collagen cross-linking enzyme lysyl oxidase [Harrison et al. 2006]. The buildup of collagen, 
together with contractile forces, allows closure of the wound. In a normal wound healing process, 
upon restoration of tissue integrity, myofibroblasts stop contracting and undergo apoptosis 
[Desmoulière A. 1995, Kis et al. 2011]. 
Even as the myofibroblasts produce new collagen, collagenases degrade it, and during a 
normal wound healing process, a balance between collagen production and degradation will be 
attained. However, fibrosis occurs when there is an imbalance between production and 
degradation, or when the myofibroblasts do not undergo apoptosis, resulting in the formation of 
a scar [Rieder et al. 2007]. 
2.2.2.4 Angiogenesis (Neovascularization) 
Along with the fibroblast – myofibroblast differentiation phase, there is a concurrent process of 
from day 4 onwards. Angiogenesis is imperative for wound healing as it provides oxygen and 
nutritional support for the new tissue. Macrophages are the first cell types to enter the wound 
bed and they release tumor necrosis factor (TNF-α), which in turn stimulates VEGF production 
by fibroblasts and keratinocytes [Frank et al. 1995]. In response, endothelial cells migrate into 
the wound bed, a process largely mediated by the FN within provisional ECM and the cytokines 
VEGF, FGF, angiopoietins and TGFβ1 released by macrophages, fibroblasts, epithelial cells 
and endothelial cells in response to either hypoxia [Brahimi-Horn et al. 2011] or high 
concentrations of lactate pyruvate [Draoui et al. 2011]. This process is accompanied by the 
degradation of the fibrin clot to facilitate migration (mediated by MMPs and serine proteases). 
The most critical pro-angiogenic factor is VEGF, which stimulates multiple components of the 
angiogenic cascade. VEGF stimulates the proliferation of endothelial cells [Tie et al. 2012] and 
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increases ECM permeability in the provisional ECM, a process necessary for angiogenesis 
[Dvorak et al. 1995]. The increase in the endothelial cell population leads to tubular formation, 
which is further driven by nitric oxide, a potent vasodilator which protects tissues from hypoxia 
and ischemia [Blantz et al. 2002]. 
When the tissue is adequately perfused, often in configurations that do not conform to those in 
the uninjured dermis, the migration and proliferation of endothelial cells slows and eventually, 
blood vessels that are no longer required undergo apoptosis [Tie et al. 2012].  
2.2.2.5 Remodeling and maturation of tissue 
Remodeling commences 4 days post-injury, but can last up to months or even years depending 
on the size of the wound. In response to TGFβ1, remodeling of the ECM begins when collagen 
deposits are in abundance. Similar to the angiogenic process of ECM degradation, MMPs and 
collagenases (secreted by fibroblasts, epidermal cells and macrophages) act to breakdown the 
early type III collagen. Fibroblasts and myofibroblasts are the key effector cells responsible for 
collagen I secretion into the surrounding extracellular space [Harrison et al. 2006], and excess 
ancillary collagen fibres are removed or replaced by the stronger type I collagen. The remaining 
fibres are subsequently reorganized to add stability and provide a suitable microenvironment to 
re-attain cellular metabolism. As remodeling takes place, the tensile strength of the wound 
eventually increases, ultimately regaining up to 80% of that of normal tissue [Lindstedt et al. 
1975]. 
Wound healing progresses in a predictable, highly regulated manner, with each stage 
characterized by a well-orchestrated cascade of factors and ECM proteins. If any of these steps 
go awry, the healing process becomes inappropriate, leading to either a chronic wound or a 
pathological condition known as scarring or fibrosis. 
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2.3 TGFβ1: A cytokine with many facets  
There are a plethora of growth factors which regulate fibrogenesis, the most prominent being 
members of the TGFβ1 family. Mammalian TGFβ1 exists in three isoforms – TGFβ1, 2 and 3. 
Despite being structurally similar, they exert diverse effects in vivo [Pelton et al. 1991]. TGFβ2 
plays a vital role in embryonic development [Roberts et al. 1992] while TGFβ3 regulates 
molecules involved in cellular adhesion and ECM formation in the cleft palate and lung 
[Kaartinen et al. 1995]. With regard to wound healing, TGFβ3 promotes scarless wound healing 
[Kohama et al. 2002, Shah et al. 1994, Ferguson et al.1996] while TGFβ1 is a well known factor 
in fibrosis. TGFβ1 is a growth factor with pleiotropic effects necessary for the maintainence of 
homeostasis in the body [Liu et al. 2011, Ruscetti et al. 2003]. A strongly regulated molecule 
during physiological events, TGFβ1 deploys both positive and negative feedback mechanisms 
[Heldin et al. 1997] and exerts its effects on hundreds of genes, resulting in dramatic geno- and 
phenotype changes [Ranganathan et al. 2007]. The focus of this thesis is on TGFβ1-induced 
fibroblast – myofibroblast differentiation.  
2.3.1 Mechanisms of TGFβ1 activation 
All mammalian TGFβ1 molecules are first synthesized as precursor molecules containing both a 
propeptide region and an inactive TGFβ1 homodimer (Figure 2). There is significant amount of 
the large latent complex (LLC) in the ECM, and, because different cellular mechanisms require 
precise levels of TGFβ1 signaling, activation of the inactive precursors allows appropriate 
mediation of TGFβ1 signaling in vivo [Annes et al. 2003]. Activation of latent TGFβ1 involves the 
liberation of TGFβ1 from the LLC from the ECM. Release of active TGFβ1 involves the 
disruption of the bonds attaching it to the latency associated peptide (LAP). Current literature 
suggests that the mechanism of TGFβ1 activation is varied and context dependent, but it is 
generally suggested that conformational changes in the LAP structure releases bioactive TGFβ1 
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and exposes TGFβ1 receptor binding sites [Khalil N et al. 1999, Biernacka et al. 2011]. This 
process is mediated by proteases, integrins, MMPs (specifically MMP-2 and MMP-9) [Wipff et al. 
2008], thrombospondin-1 [Sweetwyne et al. 2012], hydroxyl radicals from reactive oxygen 
species [Barcellos-Hoff et al. 1994] and pH [Annes et al. 2003], a mechanisms which denatures 
the LAP thereby inducing the activation of TGFβ1 [Lyons et al. 1988]. 
 
Figure 2. TGFβ1 is secreted as an inactive complex. The TGFβ1 homodimer interacts with an N-
terminal latency associated peptide (LAP) to form the small latent complex (SLC), which is unable to 
associate with its receptors. The SLC remains in the cell until it is bound by another protein known as the 
latent TGFβ1-binding protein (LTBP1) by disulfide bonds, forming a larger complex known as the large 
latent complex (LLC).  The LLC is secreted and binds to ECM components such as elastin fibrils and FN 
rich fibres [Todorovic et al. 2005]. Adapted from [Wipff et al. 2008]. 
2.3.2 TGFβ1 regulation and effects in fibrosis 
Members of the TGFβ1 family initiate signaling pathways through binding transmembrane type I 
and II receptors (TβRI, TβRII). TGFβ1 – TβRI/II interaction involves the formation of a stable 
complex that activates type I receptor kinases, triggering a cascade of signaling events that 
allows TGFβ1 to exert its biological effects. The TGFβ1 signaling pathway consists of SMADs. 
SMADs are intracellular proteins which transduce extracellular signals from TGFβ1 ligands to 
the nucleus for transcriptional activation. TGFβ1 – TβRI/II interaction phosphorylates and 
activates of R-SMADs, which bind to SMAD4 for nuclear translocation and subsequent cell-
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related transcription. Combinatorial R-SMAD activation is mediated by inhibitory SMADs (I-
SMADs), SMAD6 and SMAD7. SMAD6/7 inhibits TGFβ1 signaling through binding of their MH2 
domains to TβRI, thereby preventing the recruitment of R-SMADs [Shi et al. 2003]. TGFβ1 is a 
crucial regulator of fibroblast phenotype and function. Upon TGFβ1 stimulation, fibroblasts 
differentiate to become myofibroblasts, key effector cells in fibrotic processes. Although 
myofibroblasts are essential for tissue repair, there is still substantial controversy regarding the 
true classic markers of myofibroblasts. In TGFβ1-stimulated stromal fibroblasts, fibroblast 
activating protein-alpha (FAP-α) [Chen et al. 2009] was upregulated and has been identified as 
a myofibroblast marker. Thymus cell antigen-1 (Thy-1/CD90) was upregulated in TGFβ1-
stimulated lung and liver fibroblasts [Fries et al. 1994, Dudas et al. 2007]. However, other 
groups have reported reduced Thy-1 expression [Zhou et al. 2004], suggesting that 
myofibroblast marker expression was tissue-specific. A consensus has evolved, and 
myofibroblast hallmark markers now include elevated collagen I production and the expression 
of contractile cytoskeletal proteins, α-SMA and F-actin [Hinz et al. 2001] (Figure 3a). TGFβ1 
also promotes ECM deposition by enhancing synthesis, and altering the balance between ECM-
preserving elements such as plasminogen-activator inhibitor-1 [Ghosh et al. 2012], tissue 
inhibitor of metalloproteinases (TIMPs) [Hemmann et al. 2007] and degradative cellular cues 





Figure 3. The effects of TGFβ1 on fibroblast function and phenotype. Under TGFβ1 stimulation, (a) 
fibroblasts adopt a myofibroblastic phenotype by expressing α-SMA and elevated collagen I production; 
(b) TGFβ1-stimulated fibroblasts increase ECM deposition; and (c) there is proliferation to achieve wound 
healing.  
Other markers of the TGFβ1-mediated fibrogenic pathway include:  
i. Frizzled-8 (FZD8): a downstream effector of the TGFβ1-signaling pathway and a receptor of 
the canonical Wnt pathway, FZD8 was demonstrated to induce canonical Wnt/β-catenin 
signaling leading to gene activation [Nam et al. 2006].  
ii. NADPH-oxidase 4 (NOX4): The NADPH oxidase proteins are a source of reactive oxidative 
stress (ROS) and have been implicated in fibrogenesis. NOX4 was expressed in cardiac 
fibroblasts, pulmonary fibroblasts, hepatocytes and epithelial cells [Chan et al. 2009, 
Crestani et al. 2010]. In the lung, NOX4 maintained TGFβ1-induced myofibroblast activation 
and fibrogenic responses [Amara et al. 2010, Hecker et al. 2009, Bocchino M et al. 2010], 
and was elevated in the biopsies of IPF patients [Amara et al. 2010].  
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iii. Tetraspanin 2 (TSPAN2): TSPANs are transmembrane proteins and correlate to ECM 
production and regulation. To date, there is little evidence in the literature of the relationship 
between TSPANs and fibrosis. 
In pathological conditions, activated myofibroblasts do not undergo apoptosis [Kis et al. 2011] 
and hence become key effectors of fibrosis, leading to increased contraction and ECM 
deposition in the wound bed (Figure 4). 
 
Figure 4. Physiological and fibrotic wound healing. In physiological wound healing, the production of 
TGFβ1 is well-regulated. In fibrosis, on-going TGFβ1 signaling leads to ECM accumulation and the 
persistence of myofibroblasts in the wound. Adapted from [Rieder et al. 2007]. 
2.3.3 TGFβ1-induced fibrogenesis in vitro: constraints in the current model 
Pulsatile regulation occurs in most physiological systems and is most established in the 
endocrine system. In neuroendocrinology, neurohormone gonadotropin releasing hormone was 
demonstrated to work in a pulsatile manner to coordinate luteinizing hormone and follicle 
stimulating hormone production [Flanagan et al. 1998]; growth hormones were produced in 
individual bursts of between 30 – 90 min intervals [Martin et al. 1986]; and in the corticotropic 
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axis, the regulation of the coritcotropin-releasing hormone and arginin vasopressin led to the  
burst release of cortisol from adrenal cells [Veldhuis et al. 2008]. 
Similarly in wound healing, the production of TGFβ1 in vivo was demonstrated to be well-
coordinated. TGFβ1 is a pleiotropic factor exerting a variety of biological functions and 
regulatory molecules are present in the signaling pathway of TGFβ1 to achieve homeostasis 
and avoid prolonged myofibroblast activation [Liu et al. 2011, Ruscetti et al. 2003]. In vitro 
studies traditionally employ TGFβ1 as a culture media additive for 4 days [Hinz et al. 2001]. 
However, TGFβ1 secretion in rat dermal healing wounds was shown to be short-lived and 
produced in a “burst-like” fashion [Yang et al. 1999] – a far cry from current established fibrosis 
in vitro models (Figure 5). To date, literature on cytokine regulation in vivo is limited and there 
has been only been one report [Yang et al. 1999] documenting in vivo cytokine regulation. Their 
work emphasizes the nature of TGFβ1, a cytokine which intricately coordinates tissue repair, 
and highlights the importance of developing a physiologically relevant platform for effective anti-




Figure 5. Pulsatile release of TGFβ1 in an in vivo rat dermal wound healing model assessed over a 
14 day period. Current in vitro (red line) fibrosis models do not recapitulate in vivo (black line) conditions. 





2.4 Cell – ECM interactions 
2.4.1 The physiological ECM in wound repair 
The ECM is more than just a scaffold for wound repair. Cellular genotype and phenotype is 
largely influenced by cellular interactions with the ECM, neighboring cells, and soluble local and 
systemic biochemical cues. For example, cancer cells were suppressed to form normal tissues 
by modifying their microenvironment [Mintz et al. 1975]. In turn, cells remodel the ECM. The 
ECM of a tissue or organ is highly dependent on its origin, context and state; generally 
consisting of interstitial connective tissue and the basement membrane, which is a meshwork of 
various molecular components such as proteoglycans, glycoproteins and fibres [Aumailley et al. 
1998]. The wound microenvironment consists mainly of collagen I, which is functionally required 
to confer tensile strength and provide structural support. Resident fibroblasts contribute to the 
major development of the ECM and in turn, ECM components such as the ED-A domain of FN 
influence cellular phenotype [Serini et al. 1998]. 
2.4.2 Macromolecular crowding (MMC): recreating an in vivo microenvironment 
The interior of cells, be they of eukaryotic or prokaryotic origin is highly crowded [Fulton 1986], 
mostly because of macromolecules such as proteins, lipids, nucleic acids and carbohydrates. In 
ex vivo culture, cells are harvested from tissue and placed in a highly aqueous environment on 
TCP – a condition far removed from the actual tissue state. Current solutions in cell culture 
technologies for the recapitulation of the microenvironment include surface modifications of TCP 
and/or 3D cultivation in ECM-derived scaffolds such as collagen gels [Simkovic 1959] and 
Matrigel [Kleinman et al. 1982]. 
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2.4.2.1 MMC enhances ECM deposition and remodeling 
An alternative approach towards the recreation of a highly dense microenvironment is the use of 
MMC. MMC have important effects in cell biology and can be broadly categorized as: 1) 
accelerated protein folding under MMC [van den Berg et al. 2000]; 2) increased enzyme – 
substrate half-lives and reaction kinetics leading to enhanced product formation [Norris et al. 
2011, Lareu et al. 2007]; 3) the restoration of cellular functions (e.g transcription and DNA 
replication) under compromised environments such as adverse pH or temperature [Zimmerman 
et al. 1987, 1993]; and 4) the reversal of biochemical reactions [Somalinga et al. 2002]. Our 
group has previously demonstrated the efficacy of MMC in cell culture. MMC significantly 
enhance ECM deposition around mesenchymal stem cells [Zeiger et al. 2012] and fibroblasts 
[Chen et al. 2011]. Utilizing the biophysical approach of MMC in cell culture allows cells to 
recreate their own microenvironment to serve as a platform for advances in basic research and 
tissue engineering.  
2.4.3 Dynamic cell – ECM reciprocity 
Regulation of cellular function is characterized by close communication between cells and their 
environment (Figure 6) [Nelson et al. 2006, Bornstein et al. 2002]. This ongoing bi-directional 
crosstalk between cells and the ECM is coined as “dynamic reciprocity” [Bissell et al. 1982, 




Figure 6. Cell – ECM interactions. Cells and their ECM interact through biochemical (cytokines or 
adhesion molecules) and mechanochemical stimuli to influence each other. The ECM regulates cellular 
tension, polarity, differentiation, migration, proliferation and survival. In turn, the cell synthesizes, 
degrades and remodels the ECM. Adapted from [Mutsaers et al. 1997]. 
The ECM compromises of a network of proteins with various structural and cell regulatory 
functions. Cells are directly linked to the ECM through integrins, which is mediated though FN, 
collagen and vitronectin, laminin, CD44, syndecans, cell adhesion molecules, selectins and 
discoidins [Widgerow et al. 2010, Schultz et al. 2011]. In the ECM, integrins constitute the most 
abundant receptors mediating cell – ECM interactions as they create the link between the “outer” 
and “inner” environment of the cell. Integrins are more than just mere hooks; they act as 
transducers to give cells critical signals about changes in mechanical stiffness, the release of 
growth factors and the nature of their surroundings [Schultz et al. 2011]. The ECM also affects 
cellular function and phenotype by providing spatial cues which guide cell migration, sequester 
signaling molecules such as locally released growth factors and cytokines, all of which govern 
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cell survival, proliferation, spindle orientation (development), differentiation and provide 
structural support to tissues and organs [Page-McCaw et al. 2007]. 
Cells also influence ECM regulation and tissue architecture by directing ECM synthesis, 
degradation and remodeling [Askari et al. 2009, Schultz et al. 2011]. Cells rapidly remodel the 
ECM by synthesizing and degrading connective tissue proteins. The ECM sequesters signaling 
cues which stimulates connective tissue synthesis. ECM degradation is in turn controlled by 
cells which secrete collagenase enzymes, proteases and MMPs [Daley et al. 2008]. A clear 
example of one such cell type is the fibroblast. Fibroblasts synthesize a host of ECM 
components, as well as the enzymes involved in ECM degradation. Taken together, dynamic 
reciprocity plays major roles in all forms of biological processes such as embryogenesis and 
development, angiogenesis, regeneration and fibrogenesis [Schultz et al. 2011]. 
2.4.3.1 Dynamic reciprocity: Focus on wound healing and fibrosis 
Like most biological processes, wound healing and fibrosis involve cell – microenvironmental 
interactions, of which the ECM is a major component of.  Cell – ECM communication is highly 
regulated and coordinated in order to orchestrate a band of signals to restore biological function 
and tissue integrity. A minor perturbation in this well-controlled physiological process can lead to 
fibrosis or simply, scar formation. The role of dynamic reciprocity in wound healing as defined by 
[Nguyen et al. 2009] is discussed in the preceding text. This section highlights cell – ECM 
interactions at various stages of wound healing. 
2.4.3.1.1 Early Phase 
Within minutes of tissue damage, a barrage of signals leads to a series of events designed to 
trigger inflammation and prevent major blood loss. Platelets infiltrate the wound site and release 
cytokines (TGFβ1, TNF-α) and chemokines which serve as chemoattractants for fibroblasts and 
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neutrophils [Widgerow et al. 2010], affecting ECM function [Ignotz et al. 1986]. FN and the fibrin 
clot, designed to halt blood loss, serve as a provisional ECM to incorporate adherent sites for 
cell attachment and act as a source of growth factors, proteases and protease inhibitors 
[Roberts et al. 1990]. 
2.4.3.1.2 Cellular Phase 
Inflammation features in the early stages of the cellular phase of wound healing. Monocytes 
bind to the ECM, which enhances their phagocytic capacity and increases degradation of ECM 
debris [Zafiropoulos et al. 2008]. It also induces differentiation into macrophages, which 
increases profibrotic cytokine production [Li et al. 2006]. 
Formation of granulation tissue and angiogenesis follow. A key feature of dynamic reciprocity is 
the spatiotemporal regulation of integrin expression, leading to differential regulation patterns in 
cell adhesion dynamics, cytoskeletal organization and activation of signaling pathways [Truong 
et al. 2009].  The provisional ECM releases bioactive molecules to mediate fibroblast and 
vascular cell proliferation and fibroblast attachment to FN stimulates the production of ECM 
components – collagen, proteoglycans and hyaluronic acid [McDonald et al. 1982]. MMP 
production is a key feature at this stage, regulated by sphingosine-1 phosphate crosstalk with 
TGFβ1 to regulate MMP expression [Watterson et al. 2007]. In addition, integrin-mediated 
fibroblast attachment to collagen stimulates cellular production of MMPs [Steffensen et al. 2001], 
ultimately leading to ECM degradation and cell migration. This phase is also mediated by the 
proliferation of epithelial keratinocytes. MMPs dissolve ECM attachments so as to enable the 
keratinocytes to freely migrate through the ECM [Chen et al. 2009]. The migration of 
keratinocytes is mediated through highly specific integrin interactions as keratinocytes do not 
bind to the provisional ECM as they lack αVβ3 integrins [Kubo et al. 2001]. They instead express 
integrin subtypes which have an affinity to collagen, tenasin-C and vitronectin [Clark et al. 1996], 
29 
 
thereby relocating collagen-binding integrins from the lateral membrane of which is mediated by 
α2β1 and α3β1 integrins to the basal surface (αVβ6 integrins) of the wound. Angiogenesis occurs 
concurrently with granulation tissue formation, a process dependent on MMP-mediated ECM 
degradation that allows endothelial cell migration into the wound [Lafleur et al. 2003].  
Mechanical tension represents another feature of dynamic reciprocity in fibrosis. This is largely 
modulated by the transition from collagen III to the stronger collagen I in the ECM, due to 
fibroblast remodeling in addition to changes in protein content of the ECM. MMP-mediated ECM 
degradation disrupts ECM tension and elasticity, which in turn, modulates cell shape (via the 
cytoskeleton), mediated through integrin anchors [Parker et al. 2002]. An important regulator of 
integrin-mediated tension is the small GTPase family member, RhoA [DeMali et al. 2003]. RhoA 
regulates stress-fibre formation and facilitates FN-ECM assembly [Zhong et al. 1998]. ECM-
mediated cell shape changes affects the proliferative, migration (also mediated by cytokine 
gradients) and differentiation capabilities of the cells [Ingber et al. 1993], leading to changes in 
the mechanical properties of the remodeled ECM.  
The final stage of the wound healing process is the contraction and remodeling phase. Upon 
stimulation by profibrogenic cytokines, commonly TGFβ1, fibroblasts differentiate into contractile 
α-SMA-expressing myofibroblasts and increase synthesis of ECM proteins (collagen I, ED-A FN) 
which enhance ECM tensile strength. The ED-A splice variant of FN has been demonstrated to 
induce and enhance myofibroblast differentiation [Serini et al. 1998], demonstrating the 
influence of the ECM on the myofibroblast phenotype. Latent TGFβ1 activation from ECM stores 
also mediates myofibroblast contraction [Wipff et al. 2008]. TGFβ1 interacts with ECM proteins, 
decorin [Yamaguchi et al. 1990] and the betaglycans, to induce the synthesis of decorin and 
biglycans [Okuda et al. 1990]. Feedback signals from increased ECM protein accumulation and 
ECM proteins (including fibrillins) – TGFβ1 interactions, reduces TGFβ1 bioavailability towards 
the tail end of the reparative process [Martinez-Ferrer et al. 2010]. Myofibroblasts also continue 
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to synthesize collagen until the ECM regains its structural integrity, mediated by ECM elasticity 
and tension.  
Chronic wounds leading to scarring fail to exhibit the normal sequence of dynamic cell – ECM 
interactions due to aberrant protease levels involving the dysregulation in MMP production 
[Beidler et al. 2008, Liu et al. 2009, Rayment et al. 2008, Mwaura et al. 2006], or failed integrin 
switching at appropriates phases of wound healing [Larjava et al. 1993], ultimately leading to 
disease pathogenesis [Brem et al. 2007].  Although fibrosis cannot be solely attributed to 
dynamic cell – ECM interactions, the influence of the ECM in this well controlled physiological 
process should not be discounted. 
2.5 Epigenetics 
Epigenetics is defined as the study of heritable changes in gene expression or cellular 
phenotypes caused by mechanisms other than changes in the underlying DNA sequence. 
2.5.1 Histone structure and function 
Histones are the chief protein components of chromatin and play a role in gene regulation. 
Histones consist of DNA wound round ‘spools’ which package and order DNA into structural 
units, forming nucleosomes (Figure 7) [Felsenfeld et al. 2003]. Gene regulation is controlled 
through epigenetic or histone modifications which includes acetylation, methylation (on DNA 





Figure 7. Organization of DNA within the chromatin structure. Adapted from [Felsenfeld et al. 2003]. 
2.5.2 Mechanisms of histone modifications 
Histone acetylation and DNA methylation are the most appreciated forms of epigenetic 
modifications. Acetylation involves the addition of -COCH3 group(s) on histone tails, a process 
mediated by the histone acetyltransferase (HAT) enzyme. HAT transfers the acetyl moiety onto 
the N-terminal tails of core histones, increasing histone hydrophobicity to facilitate the binding of 
transcriptional machinery to stimulate transcription. HDACs repress transcription by removing 
acetyl groups resulting in more densely packed chromatin [Eberharter et al. 2002]. The addition 
of methyl groups to cytosine-guanine (CpG) rich regions along the DNA strand, typically in the 
proximal to promoter regions, is known as DNA methylation. This is mediated by a class of 
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enzymes known as DNA methyltransferases (DNMT). It is generally held that histone 
acetylation increases transcription, but there are notable exceptions [Deckert et al. 2001]. In 
contrast, methylated CpG regions act, in general, as transcriptional repressors, leading to 
reduced gene transcription (Figure 8) [Eberharter et al. 2002]. 
 
Figure 8. Histone modification switch. Acetylation by HAT renders chromatin in an ‘open’ state and 
permits the binding of chromatin remodeling factors to facilitate transcription.  Deacetylation by HDAC or 
DNA methylation by DNMT renders chromatin in a ‘closed’ state. Adapted from [Eberharter et al. 2002]. 
2.5.3 Histone deacetylases (HDACs) 
2.5.3.1 Classification of HDACs 
HDACs are classified based on domain organization and sequence identity into classical and 
















Classical IIA HDAC4, 5, 7, 9 Nucleus / 
cytoplasm 
Tissue 
specific Classical IIB HDAC6, 10 
Non-
classical 
III Sirtuins in 
mammals (SIRT1-
7); Sir2 in yeast 
- - NAD+-dependent 
proteins not 
affected by TSA 




Solely based on 
sequence identity 
Table 2. Classification of HDACs. HDAC classification, the associated members, subcellular location, 
tissue distribution and the basis of classification type is presented. Classical HDACs share highly 
homologous zinc-dependent catalytic domains. Modified from [Marks et al. 2009]. 
2.5.3.2 The importance of HDACs in gene regulation 
HATs and HDACs work in an orchestrated manner to regulate gene transcription (Figure 8). In 
general, HATs perform the role of transcriptional co-activators and HDACs, transcriptional de-
activators. HDACs are actively involved in gene regulation and exert effects in cellular 
processes, environmental processing (i.e. signal transduction) and diseases [Eberharter et al. 
2002]. HDAC1 and 2 are the most well studied, and play an important role in homeostasis. In 
mice, germ-line deletion of HDAC1 and HDAC3 causes early embryonic lethality [Dovey et al. 
2010, Knutson et al. 2008] and cardiac-specific deletion of HDAC1 and 2 causes neonatal 
lethality [Montgomery et al. 2007]. 
HDACs also coordinate with DNA methylation to orchestrate regulation in gene repression. In 
certain cellular processes, HDACs are recruited by both DNMTs and methylated CpG binding 
proteins (such as MeCP2 and methyl-CpG binding domain proteins), resulting in histone 
deacetylation, DNA methylation and transcriptional repression [Eberharter et al. 2002]. Although 
a predominant function of HDAC is the modification of histone and chromatin structure, HDACs 
also interact with a variety of non-histone proteins such as transcription factors and co-
regulators [Glozak et al. 2005]. Taken together, HATs and HDACs work in concert to regulate 
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gene transcription, and dysregulation of these factors can lead to aberrant processes and 
disease states. 
2.5.3.3 The involvement of HATs and HDACs in fibrosis 
In the lung, reduced HDAC activity and concomitant increased HAT activity was observed in 
bronchial biopsies obtained from patients with asthma [Ito et al. 2002], interestingly, the authors 
observed greater reduction in HDAC activity in asthmatic patients who smoked [Murahidy et al. 
2005]. A marked reduction in HDAC activity in lung parenchyma biopsies was observed in 
chronic obstructive pulmonary disease patients [To et al. 2004]. Specifically, in IPF, defective 
histone acetylation was responsible for reduced COX-II expression and correlated with disease 
severity [Coward et al. 2009]. In a separate study, authors identified HDAC4 as an important 
regulator of TGFβ1-mediated myofibroblast differentiation in normal human lung fibroblasts 
[Guo et al. 2009]. In the epithelium, HDAC4 mediated the TGFβ1-induced myofibroblastic 
differentiation of human skin fibroblasts [Glenisson et al. 2007]; and it appeared that HDAC 
activity was required for the initiation and development of SSc [Huber et al. 2007]. Also, TGFβ1 
treatment reduced histone 4 acetylation resulting in stimulation of dermal fibroblast collagen 
synthesis and myofibroblast differentiation [Bhattacharyya et al. 2009]. TGFβ1 treatment also 
induced acetylation of transcription factor Fli-1, leading to myofibroblast differentiation [Asano et 
al. 2007, Ghosh et al. 2007].  
In primary myelofibrosis, both the transcriptional factor nuclear factor-κB (NF-κB) and HDAC1/3 
were involved in the progression of myelofibrosis [Komura et al. 2005]. Further, the elevation of 
HDAC Class I, II and III isoforms suggested that HDACs were involved with disease progression 
[Wang et al. 2008]. In the heart, HDAC overexpression resulted in both atrial arrhythmia 
susceptibility and fibrosis in transgenic mice [Liu et al. 2008]. In a separate study, elevation of 
HDAC7a mRNA expression, together with increased TGFβ1 and collagen I production was 
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observed in mice with cardiac hypertrophy [Ellmers et al. 2007]. In renal fibrogenesis, HDAC2 
was a key regulator of TGFβ1-induced myofibroblast differentiation, resulting in ECM 
accumulation and EMT in the kidney [Noh et al. 2004]. Lastly, in mice injured by urethral 
obstruction, increased expression of HDAC1 and 2 was observed [Yoshikawa et al. 2007]. 
Despite being a relatively new field, increasing evidence of HDAC activity during fibrosis, and 
the promise of novel ways for modulating HDAC activity may open new therapeutic avenues to 
combat this pathology. 
2.5.4 DNA methylation: Focus on fibrosis 
DNA methylation affects a wide range of fibrotic genes. Hypermethylation of the Thy-1 and its 
subsequent silencing was observed in lung fibroblasts [Sanders et al. 2011]. More specifically, 
in IPF cells, fibrotic fibroblasts exhibited increased global DNA methylation [Huang et al. 2010].  
Hypermethylation of CpG islands in the Fli-1 promoter region in pathological fibroblasts and skin 
biopsy specimens suggested that DNA methylation mediated fibrotic manifestations in SSc 
[Wang et al. 2006]. Hypermethylation of RASAL1 (which encodes an inhibitor of the Ras 
oncoprotein), mediated by DNMT1, perpetuated fibroblast activation and renal fibrogenesis 
[Bechtel et al. 2010]. The DNA-binding protein, methyl-CpG-binding protein 2 (MeCP2) was 
demonstrated to bind directly to the α-SMA gene through DNMTs and was shown to be 
essential for myofibroblast differentiation and pulmonary fibrosis [Hu et al. 2010, 2011]. In the 
mouse model of early-stage liver fibrosis, genome-wide analysis revealed reduced DNA 
methylation, resulting in inflammation and fibrogenesis [Komatsu et al. 2012]. 
2.6 The current landscape: Advances into anti-fibrotic therapy 
The mechanisms of fibrosis, biosynthesis of collagen and its essential regulation points are well 
characterized, and many of the key mechanisms regulating fibrogenic growth factor pathways 
have been elucidated. Yet, the need for an effective anti-fibrotic agent remains unmet. Current 
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anti-fibrotic treatments (both at the commercial and academic level) target three mechanisms – 
profibrotic cytokines (mainly TGFβ1), inflammation and collagen output. 
Firstly, anti-growth factors, such as small molecule inhibitors of the TGFβ1 receptor kinases, 
neutralizing antibodies that interfere with ligand-receptor interactions, antisense oligonucleotides 
reducing TGFβ1 expression, and soluble receptor ectodomains that sequester TGFβ1 have 
been developed to intervene against excessive TGFβ1 signaling activity. A number of drugs are 
currently in clinical studies with relatively poor efficacy and it is clear that further mechanistic 
studies are required to reveal how TGFβ1 mediates fibrotic responses in order to better target 
locally acting TGFβ1 [Lukas et al. 2011]. In the commercial setting, strategies such as anti-
connective tissue growth factor (CTGF) developed by Fibrogen Inc. and the blocking of TGFβ1 
receptors (Renovo) have yet to produce convincing results in clinical trials [Huber et al. 2010, 
Varga et al. 2008, Shah et al. 1994]. Despite being a notorious profibrotic factor, the important 
physiological functions that are reliant on TGFβ1 means that inhibiting its activity may potentially 
lead to aberrant immune activation and impaired wound healing. 
Inflammation is a first-phase response of fibrogenesis and anti-inflammatory approaches have 
been developed to target fibrosis. To target inflammation, strategies based on reducing 
inflammation with corticosteroids and immunosuppressive drugs have been in clinical trials, but 
with mixed reviews [Sivakumar et al. 2008]. In liver fibrosis, the only form of reversible fibrosis, 
glucocorticoids such as prednisone and the immunosuppressant azathioprine led to the 
reversion of fibrosis [Dufour et al. 1997]. The COX-II (cyclooxygenase-II) inflammation inhibitor 
has been reported as having no effect in a study conducted with transgenic mice [Yu et al. 
2008]. The pathogenesis of fibrosis cannot be completely explained by inflammation, and anti-
inflammatory approaches have had minimal therapeutic value in attenuating fibrosis – possibly 




The collagen biosynthesis pathway is another target for anti-fibrosis therapy. The selective 
endothelin-A antagonist Darusentan reduced collagen accumulation in rat secondary biliary 
fibrosis but had no effect on α-SMA expression [El Bialy et al. 2011]. Current trials also include 
the use of prolyl hydroxylase inhibitors [Tschank et al. 1987]. Clinical trials with inhibitors (such 
as FG-4539) by Fibrogen Inc. [Langsetmo et al. 2006, FibroGen et al. 2006 press release, 
Nwogu et al. 2001] and C-proteinase inhibitors (Pfizer) have yet to produce convincing clinical 
results [Turtle et al.2004]. 
A new dimension in gene regulation has emerged with the discovery of microRNAs (miRNAs) 
and small-interfering RNAs (siRNAs). siRNA interference with the TGFβ1 signaling pathway has 
been explored. Sato et al. has outlined the knockdown of specific components involved in 
collagen biosynthesis, such as the collagen-specific intraendoplasmic chaperone HSP47, using 
vitamin-A-coupled liposomes for siRNA delivery in rats [Sato et al. 2008]. The potential of 
miRNA-29c in the down-regulation of collagen deposition in TGFβ1-induced myofibroblasts has 
also been described [Chen et al. 2009], and it is generally recognized that miRNAs are a 
promising approach towards modulating cell behavior; a plethora of possibilities exist. To the 
best of my knowledge, there has been no reported clinical miRNA trial to date, and targeting 
miRNAs in vivo will almost certainly prove to be yet another major challenge.  
Recently, a new class of epigenetic modulators known as HDAC inhibitors have recently been 
described to possess anti-fibrotic potential [Pang et al. 2010], and this will be discussed in the 
preceding text. 
2.6.1 Classification of HDACi 
HDACi represent a new group of small organic agents that are able to modulate HDAC activity. 
They are broadly divided into four categories based on structural identity: hydroxymates, cyclic 
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peptides, aliphatic acids and benzamides (Table 3) [Pang et al. 2010]. HDACi of interest, SAHA 
(marketed as Vorinostat or Zolinza™, Merck) is outlined in bold. 
HDACi Class 
Selectivity 
Chemical structure Reference 
TSA Class I/II 
HDACs 
 [Finnin et al. 
1999] 
Valproic acid Class I 
HDACs 




































 [Pang et al. 
2010] 
Table 3. Chemical structure of common HDACis. Modified from [Pang et al. 2010]. 
2.6.2 HDACi therapy in anti-fibrosis 
Numerous investigations have been conducted to address the efficacy of HDACis for both anti-
cancer therapy and neurodegenerative diseases. More recent work has described the emerging 
potential of HDACi in fibrosis. 
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Trichostatin A (TSA) is the most widely studied HDACi in both in vitro studies and in vivo models. 
In the skin, TSA downregulated TGFβ1-mediated α-SMA mRNA, protein expression and 
morphological change in cultured human skin fibroblasts [Glenisson et al. 2007]. In SSc 
fibroblasts, the inhibition of HDAC by TSA attenuated the expression of the ECM proteins 
collagen I and FN [Huber et al. 2007]. Another in vivo study demonstrated that TSA treatment 
prevented dermal accumulation of the ECM by silencing HDAC7 in the skin fibrosis mouse 
model [Hemmatazad et al. 2009]. Cystic fibrosis (CF) is an autosomal recessive genetic 
disorder caused by a mutation in the gene for the protein cystic fibrosis transmembrane 
conductance regulator (CFTR). Authors demonstrated that treatment with sodium 4-
phenylbutyrate (4-PBA) corrected the deletion of phenylalanine-508 (responsible for the 
mutation of the CFTR gene) in primary cultures of CF patients [Hutt et al. 2011]. In addition, 4-
PBA corrected cellular trafficking in CF epithelial cells [Rubenstein et al. 2000]. In the kidney, 
TSA decreased both the in vitro and in vivo activation and proliferation of renal interstitial 
fibroblasts, and reduced the expression of FN [Pang et al. 2009]. In renal tubulointerstitial injury, 
TSA and valproic acid (VPA) attenuated macrophage infiltration, colony stimulating factor-1 
induction (a chemokine involved in macrophage infiltration) and profibrotic responses 
[Yoshikawa et al. 2009].  TSA also inhibited α-SMA expression, collagen type I and III synthesis 
in HSCs [Niki et al. 1999]. In the heart, both TSA and SK-7041 (a novel hybrid synthetic HDACi 
synthesized from TSA) blocked the development of cardiac hypertrophy, mediated by the anti-
hypertrophic transcriptional regulator Krüppel-like factor 4 [Kee et al. 2006]. In pulmonary 
fibrosis, TSA prevented TGFβ1-mediated myofibroblast differentiation in normal human lung 
fibroblasts [Guo et al. 2009]. Lung fibroblasts from IPF patients show reduced COX-II 
expression; treatment with a combination of SAHA and Panobinostat (LBH589) was able to 
restore COX-II expression [Coward et al. 2009]. Lastly, our group has documented new 
evidence for the anti-fibrotic effects of SAHA [Wang et al. 2009].  
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History has dictated the precedence of HDACi therapy before the elucidation of its exact 
mechanism of action and HDACi are already clinically employed in certain disorders today. 
While the exact mechanisms are unclear, the involvement of epigenetic pathways has been 
proposed [Marks et al. 2009, Wanczyk et al. 2011, Nalabothula et al. 2011]. Taken together, the 
literature reports numerous investigations into the in vitro and in vivo potential of HDACi and 
they may prove to be effective and clinically useful anti-fibrotic agents.  
2.7 SAHA: a potential epigenetic anti-fibrotic agent? 
In an indication discovery approach, Wang et al. firstly described the anti-fibrotic effects of 
HDACi SAHA. When SAHA and TGFβ1 were added into cultures simultaneously, SAHA 
abrogated TGFβ1-effects in normal and pathological fibroblast lines by preventing the transition 
into myofibroblasts and normalized α-SMA expression and collagen deposition (Figure 9a, b). 
SAHA also inhibited serum-induced fibroblast proliferation and downregulated inflammatory 
cytokines [Wang et al. 2009]. However, SAHA was not able to attenuate or reduce α-SMA 
expression in fibroblasts exposed to TGFβ1 treatment 24h before SAHA treatment (i.e. 




Figure 9. SAHA’s emerging anti-fibrotic potential. SAHA abrogated TGFβ1-induced (a) α-SMA 
expression and (b) collagen I deposition in fibroblasts. SAHA was not able to attenuate TGFβ1-induced α-
SMA expression in fibroblasts exposed to TGFβ1 24h before SAHA. Adapted from [Wang et al. 2009]. (c) 
Growth-arrested fibroblasts were treated with or without TGFβ1 for 24h prior to 48h SAHA treatment. (d) 
Representative ICC pictures (α-SMA, red; DAPI, blue) of the cell layer. Bars indicate 500µM. Data are 
represented from two independent studies in triplicates.  
2.7.1 SAHA is cytotoxic and induces apoptosis in transformed cells 
SAHA enhanced the cytotoxic effects of SN38 (topoisomerase I inhibitor) in glioblastoma cell 
lines [Sarcar et al. 2010], DAOY and PC3 tumour cells [Schmudde et al. 2008]. Independent 
studies also demonstrated SAHA’s caspase-dependent apoptotic effects in T-cell lymphoma 
[Marks et al. 2009], breast cancer cells [Huang et al. 2000], Ewing’s sarcoma [Sonnemann et al. 
2007] and malignant pleural mesothelioma [Hurwitz et al. 2012]. Taken together, the literature 
suggests that SAHA is cytotoxic, and can induce apoptosis in transformed cells.  
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2.7.2 SAHA as a cytoskeletal modifier 
SAHA hyperacetylated α-tubulin (Figure 10), a cytoskeletal component in fibroblasts [Wang et al. 
2009]. This strongly suggested that HDAC6 (α-tubulin deacetylase), a microtubule-associated 
deacetylase was inhibited [Hubbert et al. 2002]. Independent studies have documented the 
compromised in vitro and in vivo stability of dynamic microtubules [Matsuyama et al. 2002], 
epithelial and fibroblast motility with HDAC6 inhibition [Lafarga et al. 2011, Tran et al. 2007]. 
 
Figure 10. SAHA induced hyperacetylation of histone 3 and α-tubulin. Fibroblasts were treated with 
or without TGFβ1 and SAHA for 24h. Representative (a) ICC pictures (histone 3, green; α-tubulin, red) of 
cell layer. Bars indicate 50μM; (b) immunoblots of acetylated histone 3 and α-tubulin. Adapted from 
[Wang et al. 2009]. 
2.7.3 SAHA: Faster translation towards clinical therapy 
The quest for an effective anti-fibrotic agent remains unfulfilled and the use of an FDA-approved 
drug currently in clinical use would shorten ethical and regulatory procedures, and significantly 
accelerate the time required to move into translational therapy. An FDA-approved drug means 
that: 1) promising in vitro data can be moved into preclinical animals for good reason and 2) in 
vivo data can lay the foundation for clinical studies in humans. Currently, HDACi are in clinical 
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use. For example, VPA (marketed as Depakote, Valparin and Stavzor by Pfizer, Abbott 
Laboratories and Noven Pharmaceuticals Inc. respectively) was approved as an anti-epileptic 
drug in 1967 in France and is employed as an anticonvulsant and mood-stabilising drug in the 
treatment of neuro-psychiatric and degenerative disorders [Perucca E 2002, Alvarez-
Breckinridge 2012]. LBH589 is currently in clinical trials for the treatment of Hodgkin’s 
Lymphoma, myelodysplatic syndromes and breast and prostate cancer [Revill et al. 2007].  
Recently, SAHA (Vorinostat, marketed under the name Zolinza by Merck) [Marks et al. 2007] 
and romidepson (marketed as Istodax, FK228 by Celgene) [Hahnen et al. 2008], were FDA-
approved in October 2006 and November 2009 respectively. Both drugs are currently in use for 







Materials and Methods 
This chapter describes the materials and methods employed in  the experiments 
outlined in this thesis. 
 
3.1 Fibroblast cell culture 
Normal human fetal lung fibroblasts WI-38 (CCL-75, ATCC, Manassas, VA, USA) were cultured 
in 10% fetal bovine serum (FBS) - Dulbecco’s modified eagle’s medium (DMEM) (GIBCO-
Invitrogen, Grand Island, NY, USA) in 5% CO2 at 37°C. The cells were sub-cultured using 
trypsin-EDTA (GIBCO-Invitrogen, Grand Island, NY, USA) at low passage (6-8). Fibroblasts 
were seeded at 5 x 104/well in 24-well plates or 1 x 105/well in 12-well plates in 10% FBS DMEM. 
Cells were seeded at 70% and 50% of the above mentioned density for days 7 and 14 analysis 
respectively. After 24h to allow for cell attachment in 10% FBS, the fibroblasts were growth-
arrested using serum-free DMEM for 24h. Subsequently, they were treated with or without 
5ng/ml of TGFβ1 (R&D Systems, Minneapolis, MN, USA) and 30 µg/ml L-ascorbic acid 
phosphate magnesium salt η-hydrate (Aca, Wako, Osaka, Japan) in serum-free DMEM (Figure 
11).  Thereafter, TGFβ1 treatment was removed and cultures washed twice with Hank’s 
buffered salt solution (HBSS, GIBCO-Invitrogen, Grand Island, NY, USA). Cultures were 
maintained in 0.5% FBS DMEM and 30 µg/ml aca, with medium changes every 4 days. So as 
not to overlook any changes in gene and/or protein expression, the following end-points: days 1 
(immediate), 7 (mid-term) and 14 (long-term) post-treatment were selected. In vivo TGFβ1 
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production tailed off towards day 14 [Yang et al. 1999], and this formed the basis of selecting 
the last end-point at day 14. 
 
Figure 11. Cell culture setup of single (red) and double (purple) TGFβ1 pulse(s) on growth-
arrested fibroblasts to simulate in vivo conditions. Currently, fibrosis in vitro studies employ TGFβ1 
for 4 days (blue). Traditional 4 days TGFβ1 treatment was compared to pulsatile TGFβ1 treatment. 
3.1.1 Myofibroblast generation 
WI-38 fibroblast cells, pathological IPF fibroblasts (CCL-134, ATCC, Manassas, VA, USA) and 
hypertrophic scar fibroblasts (HSF, gift from Prof. TT Phan, NUS Singapore) were cultured in 10% 
FBS DMEM.  To generate myofibroblasts, WI-38, IPF and HSF fibroblasts were treated with 




3.1.2 SAHA treatment versus TGFβ1 pulse(s) 
The kinetics of SAHA treatment versus TGFβ1 pulse(s) were evaluated using 3 independent 
models (Table 4). Fibroblast cultures were washed twice with HBSS following removal of SAHA 
or TGFβ1 and maintained in 0.5% FBS DMEM and aca till days 1 and 7 post-SAHA or TGFβ1 
removal. 
Model SAHA (5µM) for 24h and/or 4h (single) or  
2 x 4h (multiple) TGFβ1 pulse(s) 
SAHA pre-treat Yes No 
SAHA post-treat No Yes 
SAHA pre- & post-treatment Yes Yes 
Table 4. Kinetics of SAHA treatment versus TGFβ1 pulse(s). SAHA pre-; post-; pre- and post-
treatment in the TGFβ1 single (4h) and multiple (2 x 4h) pulse(s) model was evaluated. 
3.2 Sodium dodecylsulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) 
Serum-free DMEM in the last 24h of the culture period (Figure 12) was harvested and digested 
with 25μg/ml porcine gastrin mucosa pepsin (Roche, Basel, Switzerland). Collagen I deposition 
on the ECM was digested in situ with 250µg/ml porcine gastric muscosa pepsin. Extracts were 
digested in 0.1N HCl for 2h and neutralized with 1N NaOH. Extracts were then visualized under 
non-reducing conditions using 5% resolving/3% stacking SDS-PAGE gel electrophoresis as 
outlined in [Raghunath et al. 1994]. Protein bands were stained with the SilverQuest™ kit 
according to manufacturer’s protocol (Invitrogen, Carlsbad, USA). Densitometric analysis of wet 
gels was performed on the collagen α1(I)-bands with the GS-800™ calibrated densitometer and 




Figure 12. Biochemical analysis of collagen content. Serum free DMEM was used to assess the 
collagen content in culture media of the indicated follow up day, where the culture media was changed 
and harvested after 24h to analyse the collagen content. Samples were resolved using a 5%/3% SDS-
PAGE electrophoresis. 
3.3  Optical analysis: adherent cytometry 
To normalize collagen I secretion rate, fibroblasts were stained with 4′, 6-diamidino-2-
phenylindole (DAPI, Molecular Probes OR, USA) after absolute methanol fixation. Nine image 
sites covering 71% of the total well area were acquired at 2x magnification using a Nikon TE600 
fluorescence microscope with an automated Ludl stage (BioPrecision 2, Ludl Electronic 
Products Ltd) and analyzed using the Metamorph® Imaging System software (Molecular 
Devices, Downingtown, PA) as described in [Chen et al. 2009]. A nucleus was defined as a 
fluorescent region with a length of 10 – 20μM and pixel intensity value of 10 units above 
background. Normalization was evaluated as collagen I output per nuclear counts in triplicate 




Western blots were performed according to [Lareu et al. 2007]. Briefly, proteins were extracted 
from the cell layer with loading buffer comprising of 50mM Tris-HCl pH 6.8, 2% SDS, 0.1% 
bromophenol blue and 10% glycerol and protease inhibitor cocktail (Roche, Basel, Switzerland). 
Extracts were separated under non-reducing conditions on 12% resolving/3% stacking SDS-
PAGE gel electrophoresis with 5mM DTT. Proteins were electroblotted onto a nitrocellulose 
membrane. Immuno-detection was carried out in Tris-buffered saline Tween-20 at pH 7.6 
(50mM Tris-base, 150mM NaCl and 0.05% Tween 20). Membrane was blocked with 5% non-fat 
milk for 1h. Primary antibodies against α-SMA (1:500) and β-actin (1:1000) were from mouse 
(Sigma-Aldrich, St. Louis, MO) and incubated for 1.5h. Membrane was incubated for 1h with 
secondary antibody goat anti-mouse HRP (1:3000, Dako, Glostrup, Denmark). Membrane was 
washed with buffer 3 times after antibody incubation. Blots were developed with the Pierce 
Western blotting detection system (Pierce-Thermo Scientific, Rockford, IL, USA) and 
chemiluminescence signal captured with the VersaDoc Imaging System model 5000 and 
analysed with  the Quantity One v4.5.2 image analysis software (Bio-Rad, Hercules, CA). α-
SMA was detected using immunoblotting, and calibrated against β-actin within the same blot. 
3.5 Immunocytochemistry (ICC) 
Cell layers were washed with HBSS and fixed with methanol-free 3.7% formaldehyde (Pierce-
Thermo Scientific, Rockford, IL, USA) at room temperature for 15mins. The cell membrane was 
permeabilized with 0.1% Triton X-100 for 3 mins. After washes with PBS, non-specific sites 
were blocked with 3% BSA for 1h followed by incubation with primary antibody, α-SMA (1:100, 
Dako, Glostrup, Denmark) for 1.5h. Secondary antibodies were goat anti-mouse AlexaFluor594 
(1:400, Molecular Probes, OR, USA) and AlexaFluor488 phalloidin (1:100, Molecular Probes, 
OR, USA). To assess protein deposition on ECM, primary antibodies were against mouse anti-
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collagen I (1:1000, Sigma-Aldrich, St. Louis, MO), rabbit anti-fibronectin (1:100, Dako, Glostrup, 
Denmark) and rabbit anti-LTBP-1 (1:200, gift from Dr. Carl-Henrik Heldin, Helsinki, Finland). 
Secondary antibodies were from goat anti-mouse AlexaFluor594, chicken anti-rabbit AF488, 
goat anti-rabbit AlexaFluor594 (1:400, Molecular Probes, OR, USA) and AF488 phalloidin. Cell 
nuclei were counterstained with DAPI. Images were acquired with an Olympus LX71 
epifluorescence microscope (Olympus, Tokyo, Japan). All digital images were background 
subtracted based on conjugate control. 
3.6 Quantitative molecular analysis: RNA extraction, Reverse 
Transcription – Polymerase Chain Reaction (RT-PCR) 
Total RNA was isolated from cell extracts using Trizol® reagent (Invitrogen, Grand Island, NY) 
and the RNeasy mini kit (Qiagen, Valencia, CA). RNA concentration was determined using 
NanoDrop (NanoDrop Technologies, Wilmington, DE). 100ng of total RNA was reverse-
transcribed using the SuperScript III reverse transcriptase (Invitrogen, Grand Island, NY) with 
oligo(dT) primers according to manufacturer’s protocol. Real time PCR was carried out using 
2µL of cDNA, 10µL of Maxima® SYBR Green/ROX qPCR Master Mix (Thermo Fisher Scientific, 
MA, USA) and 0.3µM of primers, in a reaction volume of 20µL. All reactions were performed on 
the real-time Mx3000P (Strategene, La Jolla, CA). The thermal cycling program for all PCRs 
was: 95°C for 15mins, followed by 40 cycles of amplifications, which consisted of a denaturating 
step at 94°C for 15s, an annealing step at 55°C for 30s, and an extension step at 72°C for 30s. 
Fibrogenic genes analyzed were α-SMA, FZD8, NOX4 and TSPAN2. Primers are listed in Table 
5. The level of expression of the target genes, normalized to GAPDH was calculated using the 




Gene Primer sequence 
GAPDH Forward Primer:  5’- GTCCACTGGCGTCTTCACCA -3’ 
Reverse Primer: 5’- GTGGCAGTGATGGCATGGAC -3’ 
α-SMA  Forward Primer: 5’- TTCAATGTCCCAGCCATGTA -3’ 
Reverse Primer: 5’- GAAGGAATAGCCACGCTCAG -3’ 
FZD8 Forward Primer: 5’- AGACAGGCCAGATCGCTAACT -3’ 
Reverse Primer: 5’- AAGCGCTCCATGTCGATAAG -3’ 
NOX4 Forward Primer: 5’- GGCCAGAGTATCACTACCTCC -3’ 
Reverse Primer: 5’- GTTCGGCACATGGGTAAA -3’ 
TSPAN2 Forward Primer: 5’- TTCATGTGTGATCTGCGTGTT -3’ 
Reverse Primer: 5’- TGGGAGCGAAATAGGTTGT-3’ 
Table 5. Primer sequences of selected fibrogenic genes for quantitative RT-PCR analysis. Primers 
were designed using the Oligo6.0 bioinformatics program.  
3.7 TGFβ1 enzyme-linked immunosorbent assay (ELISA) 
Cultures were treated with 4h and 2 x 4h TGFβ1 pulse(s) and the expression of TGFβ1 
determined with a commercially available ELISA kit (Human TGFβ1 Quantikine ELISA Kit, R & 
D Systems). In accordance with the model, culture media was changed and harvested after 24h 
to analyse TGFβ1 content in the supernatant by sandwich ELISA according to specialized 
procedures as described in the manufacturer’s protocol.  
3.8 Epigenetic Assays 
3.8.1 Acetylated-Histone 3 quantitation 
Global acetyl-histone 3 (H3) was determined with a commercially available ELISA kit (PathScan 
Acetylated Histone 3 Sandwich ELISA kit, Cell Signaling Technologies). At the indicated 
endpoint, cell layers were lysed and histones extracted. Acetylated H3 levels were quantified 
according to specialized procedures as described in the manufacturer protocol. 
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3.8.2 MassARRAY: DNA extraction, Bisulfite Conversion – PCR, Spot-fire1 
Genomic DNA was isolated from cell extracts using the DNeasy mini kit (Qiagen, Valencia, CA)., 
and concentration determined using the NanoDrop (NanoDrop Technologies, Wilmington, DE). 
DNA methylation was measured with the Sequenom MassARRAY Compact System [Coolen et 
al. 2007].  Briefly, gene-specific amplification of bisulfite-treated DNA was followed by in vitro 
transcription and subsequent analysis by ECM-assisted laser desorption ionization time-of-flight 
(MALDI-TOF) mass spectrometry. Sequenom assay design and methods were according to 
procedures outlined in the manufacturer’s protocol. Briefly, 1μg DNA was bisulfite converted 
using the EZ DNA Methylation kit (Zymo Research, Irvine, CA). PCR primers specific (Table 6) 
for bisulfite converted DNA were designed using the UCSC Genome Browser [Kent et al. 2002] 
and Methprimer [Li et al. 2002]. Each of the reverse primer’s contains a T7-promoter tag for in 
vitro transcription (5’-cagtaatacgactcactatagggagaaggct-3’), and the forward primer was tagged 
with a 10mer to balance Tm (5’-aggaagagag-3’). Bisulfite-treated DNA was PCR amplified using 
the HotStar Taq Polymerase (Qiagen, Valencia, CA) in 5μL reactions and treated with Shrimp 
Alkaline Phosphatase (Sequenom, San Diego, CA) for 20 mins at 37°C and then at 85°C for 
5mins. In vitro transcription/uracil-cleavage reaction was carried out in 7μL reactions using 
Sequenom T-cleavage reagent mix. Transcription cleavage products were desalted with 6mg of 
CLEAN-Resin and 20nL spotted on a 384-pad SpectroCHIP (Sequenom, San Diego, CA) using 
a MassARRAY nanodispenser (Samsung, Seoul, South Korea). Mass spectra was acquired 
using a MassARRAY MALDI-TOF MS (Bruker-Sequenom, San Diego, CA) and peak detection, 
signal-to-noise calculations and quantitative CpG site methylation performed using proprietary 
EpiTyper software v1.0 (Sequenom, San Diego, CA). Samples that failed to give reliable PCR 
product or produced spectra with low confidence levels (<2.9 in EpiTyper) were excluded from 
analysis. For fragments that contained a single CpG site, DNA methylation was calculated by 
                                                
1
 Experiment was performed in collaboration with Dr. Allan Sheppard and Ms. Leticia Castro, Liggins 
Institute, University of Auckland, New Zealand. 
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the ratio of methylated to unmethylated fragments. Lower boundary limitations imposed by 
Sequenom analysis treat cleavage products containing multiple CpG sites as single units and 
methylation values reported were weighted averages across the unit (referred to as a CpG 
group). DNA quality and no-template controls, 0% and 100% methylated DNA was included in 
all assays.  
Amplicon Genomic 
Coordinates 
Primer Sequence CpG 
ACTA2 (1) chr10:90,750,1
87-90,750,540 



















Fwd 5’-AGTATTTTTGGTTTAGGTTGGG-3’ 17 
Rev 5’-CACAAAACTAAACATATCTAAACCCT-3’  
Table 6. Amplicons, genomic coordinates, primer sequences and predicted CpGs sites covered 
for the extended promoter regions measured. PCR specific primers were designed using the UCSC 
Genome Browser and CpG sites predicted using the Methprimer algorithm. 
3.9 Decellularization of the TGFβ1-pulsed ECM 
Fibroblasts were pulsed with or without TGFβ1 and maintained for either 1 day (early ECM, M1) 
or 7 days post-pulse (late ECM, M7); end-points derived from TGFβ1 pulse(s) characterization. 
Monolayers were washed with PBS twice then treated with 0.5% DOC (Prodotti Chimici E 
Alimentari, S.P.A. 2003030085) and supplemented with 0.5x protease inhibitor cocktail in water 
for 15 mins on ice for a total of four times. This was followed by 0.5% DOC in PBS for 15 mins 
on ice with gentle agitation for a total of two times. ECM was then washed with PBS thrice and 
incubated with 0.5mg/ml DNAse (USBiological, Massachusetts, USA) for 1h at 37°C. ECM was 
washed with PBS thrice to remove residual detergent and DNAse activity before untreated 




Figure 13. Decellularization of TGFβ1-pulsed ECM and overall cell culture setup. (a) ECM was lysed 
at 2 end-points: 1 day (M1, early ECM) and 7 days post-pulse (M7, late ECM); (b) schematic of lysis 
protocol denoting the lysis procedure. Untreated fibroblasts were seeded onto the decellularized ECM; 
and (c) treated with or without a 24h TGFβ1 pulse to analyse the ECM effects on myofibroblast induction 
and maintenance. Serum free DMEM in the last 24h of the culture period and α-SMA expression was 
used to assess myofibroblast differentiation. 
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3.10 Decellularization of MMC fibroblast ECM2 
To generate the fibroblast ECM, fibroblasts were seeded at 5 x 104/ well in 24-well plates in 10% 
FBS DMEM. 24h later, media was replaced with 0.5% FBS DMEM and neutral crowder cocktail 
according to [Chen et al. 2009, Chen et al. 2011, Zeiger et al. 2012] in the presence of ascorbic 
acid for enhanced ECM deposition. Briefly, crowder cocktail comprised of 37.5mg/ml Ficoll (Fc) 
70 and 25mg/ml Ficoll 400. After 6 days, the fibroblast ECM was washed with PBS twice, then 
treated with 0.5% DOC and supplemented with 0.5x protease inhibitor cocktail in water for 15 
mins on ice for a total of four times. This was followed by 0.5% DOC in PBS for 15 mins with 
gentle agitation. ECM was washed with PBS thrice and incubated with 0.5mg/ml DNAse for 30 
mins at 37°C. ECM was washed with PBS for three times to remove residual detergent and 
DNAse activity before myofibroblasts were seeded onto the decellularized ECM (Figure 14). 
  
                                                
2
 Experiment (technical assistance) was performed by Mr. Sebastian Kress (Bayerische Julius-





Figure 14. Decellularization of fibroblast ECM. (a) Schematic of lysis protocol denoting lysis steps. 
Myofibroblasts were seeded onto decellularized fibroblast ECM; (b) fibroblasts were treated with or 
without a 24h TGFβ1 pulse to analyse ECM effects on re-seeded myofibroblasts. Serum free DMEM in 
the last 24h of the culture period and α-SMA expression was used to assess the effects of the normal 
fibroblast ECM on the myofibroblast phenotype. 
3.11 MTS Assay 
Fibroblasts were treated with 4 days of TGFβ1 treatment to induce myofibroblast formation 
(Figure 11). Thereafter, TGFβ1 was removed and the myofibroblasts treated with SAHA (Alexis 
Biochemicals, Exeter, UK) at concentrations of 0, 1, 2.5, 5 and 10µM. Cell viability was 
determined using a commercially available colorimetric MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) CellTiter 96® AQueous One Solution 




3.12 Apoptosis and cytotoxicity analysis 
SAHA-induced apoptosis and cytotoxicity was measured in fibroblasts and myofibroblasts. 
Growth-arrested fibroblasts were treated with and without TGFβ1 for 4 days (Figure 11). 
Thereafter, media was replaced with 5µM SAHA and cultures harvested and analysed at days 1, 
2 and 4 post treatments. Apoptosis and cytotoxicity was determined using the commercial 
ApoTox-Glo™ assay (Promega, Madison, Wisconsin, USA) as indicated by the manufacturer 
protocol. 
3.13 Mechanical and locomotion analysis3 
3.13.1 Cell migration analysis 
A wound healing assay was used to analyse cell migration. Commercial cell culture inserts of 
width 500µM ± 50µM (Ibidi GmBH, Martinsried, Germany) surrounded by two chambers were 
adhered in the center of uncoated 12-well plates (Figure 15). 70µL of fibroblast cell suspension 
was seeded/chamber and the remainder outside the chambers to a final density of 1 x 105/well. 
Cultures were maintained in 10% FBS DMEM to permit cell adhesion. After 24h, culture medium 
was removed and replaced with or without 5ng/ml of TGFβ1 in 0.5% FBS DMEM for 3 days as 
indicated by the manufacturers’ protocol. Subsequently, culture inserts and cytokine containing 
medium was removed and replaced with or without 5µM of SAHA in 0.5% FBS DMEM. Wound 
closure was monitored at various time intervals until day 3 post-SAHA treatment. Images were 
acquired with an inverted Nikon Eclipse TS100 microscope (Nikon, Tokyo, Japan) and Nikon 
Digital Sight camera (Nikon, Tokyo, Japan). Cell migration into scratch area was quantitated 
using ImageJ analysis. 
                                                
3
 Technical assistance was provided by Ms. Stella Chee. Experimental design and analysis of results was 




Figure 15. Cell culture inserts simulating an in vitro wound healing assay. (a) Schematic of Ibidi cell 
culture inserts; (b) 2D schematic of cell culture insert in culture plates. Fibroblasts are seeded in and out 
of the chambers and migration monitored by live cell imaging into scratch area at various time intervals. 
3.13.2 Gel contraction analysis 
SAHA-induced myofibroblast contractility was determined using the commercial gel contraction 
kit (Cell Bio Labs, San Diego, CA, USA) according to manufacturers’ protocol. Briefly, fibroblasts 
were mixed in collagen I gels and treated with or without TGFβ1 in 0.5% FBS DMEM. After 48h 
required for stress to develop in the ECM, stressed gels were released (using a sterile spatula) 
and cytokine containing culture media replaced with or without 5µM of SAHA. Using a ruler, the 
contraction index (diameter of gel) was measured at various time intervals until 3 days post-
SAHA treatment. 
3.14 Statistical Analysis 
Statistical analysis was performed using the GraphPad Software Inc. (San Diego, CA, USA). 
The statistical significance between groups was determined using the Student’s t-test, two-tailed 
distribution with unequal variance. Probability values of p<0.05 (95% confidence interval) in 




Chapter 4  
Results 
This chapter presents the results of the core findings of the projec t. An in vitro 
fibrosis model focusing on pulsatile TGFβ1 release is presented. SAHA’s anti -
fibrotic and cytoskeletal effects are presented.  
 
4.1 Development of a physiologically relevant in vitro fibrosis model 
Currently, no in vitro fibrosis model accurately depicts the physiological nature of TGFβ1 
secretion in vivo and it is essential to develop an in vitro platform for wound healing and fibrosis. 
The aim of the platform is one that a) models in vivo pulsatile regulation of TGFβ1 as reported 
by [Yang et al. 1999]; and simulates b) physiological; and c) pathological wound healing. 
Classical myofibroblast markers α-SMA and F-actin expression, collagen I production and 
selected fibrogenic genes from a microarray on TGFβ1-treated fibroblasts were used to 
characterize the model. 
4.1.1 Short-term analysis of TGFβ1 pulse showed no overt increase in α-SMA 
expression 
To select pulse time-points and endpoints to investigate, it was important to understand the 
short-term kinetics of TGFβ1. Growth-arrested fibroblasts were exposed to a TGFβ1 pulse for 
selected time periods. Short-term analyses of a TGFβ1 pulse showed no overt increase in α-
SMA expression immediately after a pulse. However, after 16h, a slight increase in α-SMA 
expression was observed (Figure 16). Results suggested that cells required more than 16h to 
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differentiate and upregulate the synthesis of the α-SMA protein. Therefore, short-term analysis 
after a TGFβ1-pulse was insufficient for an in vitro screening platform.  
 
Figure 16. Short-term analysis of α-SMA expression immediately after TGFβ1 pulse showed no 
overt increase in α-SMA expression. After the pulse, cytokine containing medium was withdrawn, cell 
cultures washed and analyzed thereafter. This figure illustrates the raw data. For all other results, both 
raw and densitometric data are shown. 
4.1.2 4 days TGFβ1 treatment lasts for 14 days 
Fibroblasts are traditionally exposed to 4 days of TGFβ1 treatment to generate myofibroblasts 
[Hinz et al. 2001]. We therefore, assessed the effects of 4 days TGFβ1 treatment on the 
creation and maintenance of the myofibroblast phenotype (Figure 11) and established that 




Figure 17. 4 days of TGFβ1 treatment had long-lasting effects. (a) Normalized densitometric SDS-
PAGE analysis of the 24h collagen secretion rate by induced fibroblasts; (b) densitometric analysis of α-
SMA was normalized to β-actin expression; (c) representative SDS-PAGE; (d) representative 
immunoblots at days 1, 7 and 14 post-treatment and (e) representative ICC pictures (α-SMA, red; 
phalloidin, green; DAPI, blue) of cell layer. Bars indicate 500µM. *p < 0.05 versus respective untreated 
controls. Data are represented as mean ± S.D, calculated from three independent studies in triplicates, 
and expressed as -fold changes over respective controls. 
4.1.3 A 0.5h TGFβ1 pulse lasted for up to 7 days 
We proceeded to investigating the effects of a single TGFβ1 pulse on the creation and 
maintenance of the myofibroblast phenotype. Here, we demonstrated that a single TGFβ1 pulse, 
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as short as 0.5h, induced myofibroblast phenotype maintenance as indicated by increased 
expression of α-SMA and collagen I production, for up to 7 days post-pulse (Figure 18). 
Collagen I production and α-SMA expression was reversed to baseline level 14 days later.  
 
Figure 18. A single pulse of TGFβ1 had long-lasting effects. Normalized densitometric SDS-PAGE 
analysis of the 24h collagen secretion rate by induced fibroblasts after (a) 0.5h, (b) 4h TGFβ1 pulse; (c – 
d) representative SDS-PAGE of the 0.5h and 4h pulse respectively. Densitometric analysis of α-SMA was 
normalized to β-actin expression for the (e) 0.5h, (f) 4h TGFβ1 pulse; (g – h) representative immunoblots 
of 0.5h and 4h pulse respectively and (i) representative ICC pictures (α-SMA, red; phalloidin, green; DAPI, 
blue) from the 4h TGFβ1-pulsed cell layers. Bars indicate 500µM. *p < 0.05 versus respective untreated 
controls. Data are represented as mean ± S.D, calculated from three independent studies in triplicates, 
and expressed as -fold changes over respective controls. 
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To better characterize the single pulse model, I selected other fibrotic genes pertaining to the 
TGFβ1 signaling pathway or collagen regulation. mRNA levels of α-SMA (ACTA2), FZD, NOX4 
and TSPAN2 were found to be elevated 24h post-TGFβ1 pulse (Figure 19). 
 
Figure 19. Selected fibrogenic genes were markedly increased 24h post-pulse. mRNA expression of 
α-SMA: (a) 0.5h, (b) 4h; FZD8: (c) 0.5h, (d) 4h; NOX4: (e) 0.5h, (f) 4h; and TSPAN2: (g) 0.5h, (h) 4h 
TGFβ1 pulse. With the exception of FZD8 and TSPAN2, mRNA expressions of the aforementioned 
fibrotic genes were at baseline levels at days 7 and 14. *p < 0.05 versus respective untreated controls. 
Data are represented as mean ± S.D, calculated from three independent studies in triplicates, and 
expressed as -fold changes over respective controls. 
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4.1.4 Multiple pulses potentiated effects 
Further, we investigated the effects of an additional TGFβ1 pulse and demonstrated that an 
additional TGFβ1 pulse, administered 24h later, potentiated the myofibroblast phenotype 
maintenance as observed from persistent increased collagen I production and α-SMA 





Figure 20. Multiple pulses of TGFβ1 potentiated effects. Normalized densitometric SDS-PAGE 
analysis of the 24h collagen secretion rate by induced fibroblasts after (a) 2 x 0.5h, (b) 2 x 4h TGFβ1 
pulses; (c – d) representative SDS-PAGE of 2 x 0.5h and 2 x 4h pulses respectively. Densitometric 
analysis of α-SMA was normalized to β-actin expression for the (e) 2 x 0.5h, (f) 2 x 4h TGFβ1 pulses; (g – 
h) representative immunoblots of 2 x 0.5h and 2 x 4h pulses respectively and (i) representative ICC 
pictures (α-SMA, red; phalloidin, green; DAPI, blue) of the 2 x 4h TGFβ1-pulsed cell layers. Bars indicate 
500µM. *p < 0.05 versus respective untreated controls. Data are represented as mean ± S.D, calculated 
from three independent studies in triplicates, and expressed as -fold changes over respective controls. 
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mRNA expression of selected fibrogenic genes were quantified and established to be elevated 
up to 7 days post-TGFβ1 pulses (Figure 21). 
 
Figure 21. Selected fibrogenic genes were increased for up to 7 days post TGFβ1-pulses. mRNA 
expression of α-SMA: (a) 2 x 0.5h, (b) 2 x 4h; FZD8: (c) 2 x 0.5h, (d) 2 x 4h; NOX4: (e) 2 x 0.5h, (f) 2 x 4h; 
and TSPAN2: (g) 2 x 0.5h, (h) 2 x 4h TGFβ1 pulses. With the exception of TSPAN2, mRNA expressions 
of the aforementioned fibrotic genes were at baseline levels at days 7 and 14. *p < 0.05 versus respective 
untreated controls. Data are represented as mean ± S.D, calculated from three independent studies in 
triplicates, and expressed as -fold changes over respective controls. 
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4.2 Investigating the memorized effects of TGFβ1 pulses 
The previous results suggests the establishment of a stable phenotype after TGFβ1 pulses and 
allows for further exploration of the mechanistic effects underlying the model. Fibroblast – 
myofibroblast differentiation is complex and highly regulated but understanding the mechanism 
will allow precise targeting for future anti-fibrotic therapies. Here, we focus on the 4h and 2 x 4h 
pulses to investigate: 1) autocrine TGFβ1 production; 2) epigenetic effects and 3) cell – ECM 
interactions based on the notion of matrix reciprocity.  
4.2.1 Single TGFβ1 pulses triggered sustained autocrine TGFβ1 production 
Cell layers were washed extensively with HBSS to remove recombinant TGFβ1. However, 
substantial levels of endogenously produced of active TGFβ1 levels were detectable in culture 
media 24h post-pulse and had reverted to baseline at days 7 and 14 (Figure 22a – b). In 
contrast, we observed an increased amount of latent TGFβ1 levels at all assessed timepoints as 




Figure 22. TGFβ1 pulse(s) induced elevated active and latent TGFβ1 secretion in fibroblasts. 
Circulating active TGFβ1 was elevated 24h post-pulse in the (a) 4h; and (b) 2 x 4h TGFβ1-pulsed 
fibroblasts. Acid treatment activated latent TGFβ1 storage and resulted in elevated expressions of TGFβ1 
levels at all assessed end-points in the (c) 4h; and (d) 2 x 4h model. *p < 0.05 versus respective 
untreated controls. Data are represented as mean ± S.D, calculated from four independent studies in 
triplicates, and expressed as -fold changes over respective controls. 
4.2.2 No apparent evidence for epigenetic modifications in selected fibrosis-related 
genes after TGFβ1 pulsing 
SAHA hyperacetylated histone-3 [Wang et al. 2009] leading to the speculation that acetylation 
changes mediated gene transcription after TGFβ1 treatment. However, we demonstrated that a 
single 4h TGFβ1 pulse did not affect global H3 acetylation levels when cultures were analysed 
immediately after SAHA treatment and 24h post-SAHA treatment. HDACi SAHA was used as a 




Figure 23. H3 acetylation levels remain unchanged after a TGFβ1 pulse. Acetylation levels in TGFβ1-
pulsed fibroblasts were analyzed immediately and 1 day post-pulse. SAHA (HDACi) was used as the 
positive control in this assay. *p < 0.05 versus respective untreated controls. Data are represented as 
mean ± S.D, calculated from two independent studies in triplicates, and expressed as optical density 
450nm. 
We proceeded onto investigating DNA methylation changes and assessed the DNA methylation 
profiles in the proximal promoter regions of the ACTA2 and COL1A1 genes after TGFβ1 
pulse(s). DNA methylation levels in these two genes were established to be unaffected by 
TGFβ1 pulse(s) (Table 7).  
Amplicon Targeted 
CpG’s 
4h TGFβ1 pulse 2 x 4h TGFβ1 pulse 
Day 1 Day 7 Day 14 Day 1 Day 7 Day 14 
ACTA2 (1) 19 = = = = = = 
ACTA2 (2) 26 = = = = = = 
COL1A1 (1) 19 = = = = = = 
COL1A1 (2) 17 = = = = = = 
Table 7. ACTA2 and COL1A1 were not regulated by DNA methylation changes in response to 
TGFβ1 pulse(s). Changes in methylation levels > 10% were considered significant. ACTA2 and COL1A1 
genes express low methylation levels and displayed no overt changes with TGFβ1 pulse(s).  
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4.2.3 Trypsin-EDTA passaging attenuated the myofibroblast phenotype 
If the memory was due to cell intrinsic factors, the myofibroblast phenotype should be 
propagated over passages. We therefore, investigated if the phenotype was maintained after 
trypsin-EDTA passaging and established the attenuation of the myofibroblasts phenotype after 4 
days to TGFβ1 treatment to generate myofibroblasts (Figure 24). These results indicate that the 
memorized effects after TGFβ1 pulses were not due an intrinsic change in the cell, but likely 
dependent on the microenvironment of the cell. We therefore proceeded to investigate the 




Figure 24. Trypsin-EDTA passaging attenuated the myofibroblast phenotype. (a) Cell culture setup 
of TGFβ1 treated myofibroblasts and subsequent sub-culture. Briefly, cells were treated with and without 
TGFβ1 for 4 days (benchmark for myofibroblast culture) and subsequently trypsin-EDTA passaged and 
re-plated onto TCP. (b) Normalized densitometric SDS-PAGE analysis of the 24h collagen secretion rate 
by induced fibroblasts; (c) representative SDS-PAGE; (d) densitometric analysis of α-SMA normalized to 
β-actin expression; (e) representative immunoblots and (f) ICC pictures (α-SMA, red; phalloidin, green; 
DAPI, blue) of sub-cultured myofibroblasts. Bars indicate 500µM. *p < 0.05 versus respective untreated 
controls. Data are represented as mean ± S.D, calculated from three independent studies in triplicates, 
and expressed as -fold changes over respective controls. 
71 
 
4.2.4 ECM generated under TGFβ1-pulses induced the myofibroblast phenotype 
To investigate the phenotypic influence of ECM-mediated (produced after TGFβ1-pulses) 
myofibroblast induction, fibroblasts were pulsed with or without TGFβ1 for 4h and 2 x 4h and 
then removed by detergent treatment. The resulting decellularised ECM (Figure 25) was re-
seeded with previously untreated fibroblasts. We observed that particularly doubly TGFβ1-
pulsed matrices were able to induce a myofibroblastic phenotype (Figure 26). Furthermore, 
myofibroblast-inducing properties were strongest in matrices decellularised 1 day post-pulse 
and were slightly diminished (only α-SMA expression increased, Figure 26a, d, g) in matrices 7 
days after decellularisation. We proceeded onto identifying a protein which may be responsible 
for myofibroblast induction in the untreated fibroblasts, and speculated that the induction of 
phenotype was attributed to latent TGFβ1 storage on the ECM. Here, we demonstrated 




Figure 25. TGFβ1-pulsed ECM was free from DNA and actin residues. Representative immunoblots 
of (a) 4h; and (b) 2 x 4h TGFβ1-pulsed ECM. Elevated collagen I and FN expression was observed in 
TGFβ1-treated ECM; representative SDS-PAGE gels of (c) 4h; and (d) 2 x 4h TGFβ1 ECM; and 
representative ICC pictures of (e) early (decellularised 1 day post-pulse); and (f) late (decellularised 7 
days post-pulse) ECM (collagen I, red; FN and phalloidin, green; DAPI, blue). Legend: “L” denotes 




Figure 26. TGFβ1-pulsed ECM influenced the myofibroblast phenotype, with pronounced effects 
with multiple pulses and the early (M1) ECM. (a) Normalized densitometric SDS-PAGE analysis of the 
24h collagen secretion rate; representative SDS-PAGE gels of (b) early M1; and (c) late M7 ECM. (d) 
Densitometric analysis of α-SMA was normalized to β-actin expression; representative immunoblots of (e) 
M1; and (f) M7 ECM. (g) Representative ICC pictures (α-SMA, red; phalloidin, green; DAPI, blue) of the 
cell layer. Tissue culture plastic (TCP) ctrl, ECM ctrl and cells reseeded onto 4h and 2 x 4h TGFβ1-pulsed 
ECM ICC images were modified to highlight α-SMA expression. Bars indicate 500µM. *p < 0.05 versus 
respective untreated controls. Data are represented as mean ± S.D, calculated from three independent 
studies in triplicates, and expressed as -fold changes over respective TCP controls. Legend: TGFβ1 ECM: 
“+” denotes a 4h; and “++” 2 x 4h TGFβ1 pulse(s) on decellularized ECM. TGFβ1 Cells: “+” denotes a 24h 




Figure 27. ECM decellularised 1 day post-pulse exhibited elevated LTBP-1 expression. (a) 
Representative ICC pictures (LTBP-1, red) of the 4h and 2 x 4h TGFβ1-pulsed M1 and M7 ECM. (b) 
Schematic illustrating the proposed mechanism. TGFβ1-pulsed M1 ECM expressed elevated levels of 
LTBP-1. We propose that LAP releases TGFβ1 and this in turn, activates fibroblast – myofibroblast 
differentiation. 
4.2.5 Normal fibroblast ECM down-modulated the myofibroblast phenotype 
From a therapeutic perspective, it would be beneficial if the ECM could normalize or down-
modulate myofibroblast expression. In these studies, MMC (Fc cocktail) was employed to 
enhance ECM deposition (Figure 28). Subsequently, normal fibroblast ECM were decellularized 
and confirmed to be free from DNA and actin residues (Figure 29). Fibroblasts (WI-38, and 
pathological: hypertrophic scar (HSF) and idiopathic pulmonary (IPF) fibroblasts) do not 
intrinsically express α-SMA when cultured without TGFβ1 on TCP. Therefore, fibroblasts were 
treated with TGFβ1 for 4 days (current ‘gold standard’) to generate myofibroblasts and 
passaged using the bacillus polymyxa-derived protease, Dispase, as α-SMA expression was 
preserved when the correct enzyme treatment was applied (Figure 30). This is likely because 
Dispase does not disrupt the integrity of the cell membrane as it cleaves collagen IV, FN and to 
a lesser extent, collagen I [Ludwig et al. 2006]. Decellularized fibroblast ECM was observed to 
reduce to and reduce below fibroblast levels, collagen I production in fetal lung WI-38 (Figure 31) 
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and HSF myofibroblasts (Figure 32) respectively. α-SMA expression, however, remained 
unchanged from TCP test control (myofibroblasts) expression. In contrast, normal fibroblast 
ECM appeared to have no effect on the phenotype of IPF myofibroblasts (Figure 33).  
 
Figure 28. Collagen I and FN deposition on ECM were increased in the presence of a Fc cocktail. 
Fibroblasts were cultured for a total of 7 days. (a) Representative ICC pictures (collagen I, red; FN, green; 
DAPI, blue). (b) Normalized densitometric SDS-PAGE analysis and (c) representative SDS-PAGE of 
collagen deposition by fibroblasts. Bars indicate 500µM. *p < 0.05 versus uncrowded control. Data are 
represented as mean ± S.D, calculated from three independent studies in triplicates, and expressed as -





Figure 29. Decellularization of MMC normal fibroblast ECM. Fibroblasts were cultured in the presence 
of MMC for 7 days and decellularized thereafter. The absence of actin and DNA residues was observed 
in the decellularised ECM. Representative (a) ICC pictures (collagen I, red; phalloidin, green; DAPI, blue); 
(b) SDS-PAGE of collagen I deposition; and (c) β-actin immunoblot. Legend: “L” denotes decellularized 
ECM and “UL” the unlysed ECM (positive ECM control). 
 
Figure 30. Dispase passaging reduced but preserved the myofibroblast phenotype. Fibroblasts (WI-
38, HSF and IPFs) were treated with or without TGFβ1 for 4 days. Thereafter, cultures were passaged 
using Dispase and re-seeded onto TCP. Cultures were maintained for further 7 days. Representative ICC 




Figure 31. Fibroblast ECM reduced to fibroblast level collagen I production in WI-38 
myofibroblasts. (a) Representative ICC pictures (α-SMA, red; phalloidin, green; DAPI, blue). Bars 
indicate 500µM. Negative controls and test conditions images were modified to highlight α-SMA 
expression (first 4 columns). (b) Normalized densitometric SDS-PAGE analysis of the 24h collagen 
secretion rate; (c) representative SDS-PAGE; (d) densitometric analysis of α-SMA normalized to β-actin 
expression; and (e) representative immunoblots. *p < 0.05 versus TCP negative control. *p < 0.05 versus 
TCP test control (myofibroblasts). Data are represented as mean ± S.D, calculated from duplicate studies 




Figure 32. Fibroblast ECM reduced below fibroblast levels collagen I production in HSF 
myofibroblasts. (a) Representative ICC pictures (α-SMA, red; phalloidin, green; DAPI, blue). Bars 
indicate 500µM. Negative controls and test conditions images were modified to highlight α-SMA 
expression (first 4 columns). (b) Normalized densitometric SDS-PAGE analysis of the 24h collagen 
secretion rate; (c) representative SDS-PAGE; (d) densitometric analysis of α-SMA normalized to β-actin 
expression; and (e) representative immunoblots. *p < 0.05 versus TCP negative control. *p < 0.05 versus 
TCP test control (myofibroblasts). Data are represented as mean ± S.D, calculated from duplicate studies 




Figure 33. Fibroblast ECM had no effect in IPF myofibroblasts. (a) Representative ICC pictures (α-
SMA, red; phalloidin, green; DAPI, blue). Bars indicate 500µM. Negative controls and test conditions 
images were modified to highlight α-SMA expression (first 4 columns). (b) Normalized densitometric SDS-
PAGE analysis of the 24h collagen secretion rate; (c) representative SDS-PAGE; (d) densitometric 
analysis of α-SMA normalized to β-actin expression; and (e) representative immunoblots. *p < 0.05 
versus TCP negative control. Data are represented as mean ± S.D, calculated from duplicate studies in 
triplicates, and expressed as -fold changes over respective controls. 
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4.3 Revisiting SAHA’s anti-fibrotic potential 
We have shown that epigenetic modifications (histone acetylation / DNA methylation) were not 
responsible for the memorized effects of TGFβ1-pulsed treatments. However, HDACi SAHA has 
been described to affect myofibroblast differentiation and collagen targets [Wang et al. 2009]. 
Alternative targets of SAHA are microtubules which are important for cell locomotion properties. 
Although SAHA was not able to abrogate TGFβ1 effects after cells were treated with TGFβ1, 
and this appears to be due to physiological limitations. We therefore aimed to: a) assess the 
anti-fibrotic effects of SAHA in conjunction with TGFβ1-pulses in fibroblasts; and to b) establish 
the mechano-effects of SAHA on myofibroblasts as this may provide an additional consideration 
for anti-fibrotic therapy.  
4.3.1 IC50 of SAHA was 5µM 
Long-term exposure to SAHA (i.e. more than 72h) was observed to result in cell death. The 
IC50 (half maximal inhibitory concentration) value of SAHA in fibroblasts was 5µM [Wang et al. 
2009]. Growth-arrested fibroblasts were treated with 4 days to TGFβ1 to generate 
myofibroblasts. Thereafter, cytokine containing media was removed and replace with varying 
concentrations of SAHA. Cultures were harvested at days 3 and 7 post-SAHA treatment. The 
IC50 concentration of SAHA in myofibroblasts was assessed using the MTS assay, and 





Figure 34. IC50 value of SAHA in myofibroblasts was 5µM. Fibroblasts were treated with 4 days of 
TGFβ1 to generate myofibroblasts and the IC50 value of SAHA evaluated from the best-fit linear equation 
at days 3 (where y = -0.0328x + 0.5485) and 7 (where y = -0.0346x + 0.3579) post-treatment. *p < 0.05 
versus respective untreated controls. Data are represented as mean ± S.D, calculated from two 
independent studies in triplicates, and expressed as optical density 490nm. 
4.3.2 SAHA induced early apoptosis in myofibroblasts 
Previous reports documented that SAHA induced apoptosis in transformed cells. We therefore 
sought to compare SAHA’s cytotoxic and apoptotic effects in fibroblasts and myofibroblasts 
using an MTS assay. Cytotoxicity was quantitated by measuring dead cell protease activity 
released from cells that have lost its membrane integrity (bis-AAF-R110: bis-alanylalanyl-
phenylalanyl-rhodamine 110. Apoptosis was determined by measuring luminogenic caspase-3/7 
activity. SAHA was non-cytotoxic and induced early (24h after SAHA treatment) apoptosis in 





Figure 35. 5µM SAHA was non-cytotoxic and induced early apoptosis in myofibroblasts. (a) 
Fluorogenic bis-AAF-R110 (bis-alanylalanyl-phenylalanyl-rhodamine 110) was used to measure dead cell 
protease activity released from cells that have lost its membrane integrity. (b) Apoptosis was determined 
by measuring luminogenic caspase-3/7 activity. 24h post-SAHA treatment, myofibroblasts expressed 
elevated levels of capase-3/7 activity. *p < 0.05 versus respective untreated fibroblasts controls. Data are 
represented as mean ± S.D, calculated from two independent studies in triplicates, and expressed as 
relative fluorescence or luminescence units.  
4.3.3 SAHA treatment versus TGFβ1 pulse(s) 
Using the in vitro wound healing platform based on the long-lasting effects of TGFβ1 pulses, 
SAHA efficacy in conjunction with 4h or 2 x 4h TGFβ1 pulse(s) was investigated.  
4.3.3.1 SAHA pre-treatment displayed short-term TGFβ1 effects with a single pulse  
To investigate SAHA’s protective effects on pulsed myofibroblast formation, we assessed the 
efficacy of 24h of SAHA pre-treatment before the administration of TGFβ1 pulse(s). We 
observed that 24h of SAHA treatment before a 4h TGFβ1 pulse reduced below fibroblast levels, 
collagen I and α-SMA expression 1 day, but not 7 days post-pulse (Figure 36). However, 24h of 
SAHA pre-treatment appeared to have no effect on myofibroblast differentiation when 




Figure 36. SAHA pre-treatment reduced to fibroblast levels, collagen I production and α-SMA 
expression after a single TGFβ1 pulse. (a) Cell culture setup of SAHA pre-treatment on growth-
arrested fibroblasts for 24h followed by a 4h TGFβ1 pulse. (b) Normalized densitometric SDS-PAGE 
analysis of the 24h collagen secretion rate by induced fibroblasts; (c) densitometric analysis of α-SMA 
normalized to β-actin expression; representative (d) SDS-PAGE; (e) immunoblots and (i) ICC pictures (α-
SMA, red; phalloidin, green; DAPI, blue) of the 4h TGFβ1-pulsed cell layers. Bars indicate 500µM. *p < 
0.05 versus respective untreated controls. *p < 0.05 versus respective TGFβ1 (positive) myofibroblast 
controls. Data are represented as mean ± S.D, calculated from three independent studies in triplicates, 




Figure 37. SAHA pre-treatment had no effect on double TGFβ1 pulses. (a) Cell culture setup of 
SAHA pre-treatment on growth-arrested fibroblasts for 24h followed by 2 x 4h TGFβ1 pulses, 
administered over 2 consecutive days. (b) Normalized densitometric SDS-PAGE analysis of the 24h 
collagen secretion rate by induced fibroblasts; (c) densitometric analysis of α-SMA normalized to β-actin 
expression; representative (d) SDS-PAGE; (e) immunoblots and (i) ICC pictures (α-SMA, red; phalloidin, 
green; DAPI, blue) of 2 x 4h TGFβ1-pulsed cell layers. Bars indicate 500µM. *p < 0.05 versus respective 
untreated controls. Data are represented as mean ± S.D, calculated from three independent studies in 
triplicates, and expressed as -fold changes over respective controls. 
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4.3.3.2 SAHA post-treatment normalized short-term TGFβ1 effects 
We proceeded to assess if SAHA would prevent myofibroblast induction and maintenance after 
fibroblasts were treated with pulse(s) of TGFβ1. To do so, we treated fibroblasts with SAHA 
immediately after treatment with TGFβ1 pulses. Here we show that in comparison with the 
TGFβ1-induced myofibroblasts, SAHA post-treatment normalized and reduced collagen I 
production 1 and 7 days, respectively, post-SAHA treatment. α-SMA expression however, was 
only reduced 1 day post a single 4h TGFβ1 pulse (Figure 38). Characterising the effects of 
SAHA post-treatment in conjunction with double TGFβ1 pulses, we demonstrate that in 
comparison with the myofibroblast controls, SAHA post-treatment reduced collagen I production 
1 and 7 days post-pulse, and reduced α-SMA expression 1 day post-pulse only (Figure 39), 






Figure 38. SAHA post-treatment normalized short-term TGFβ1-effects in the single pulse model. 
SAHA exhibited limited effects on α-SMA expression but reduced collagen production. (a) Cell culture 
setup of a 4h TGFβ1 pulse on growth-arrested fibroblasts, followed by SAHA post-treatment for 24h. (b) 
Normalized densitometric SDS-PAGE analysis of the 24h collagen secretion rate by induced fibroblasts; 
(c) densitometric analysis of α-SMA normalized to β-actin expression; representative (d) SDS-PAGE; (e) 
immunoblots and (i) ICC pictures (α-SMA, red; phalloidin, green; DAPI, blue) of 4h TGFβ1-pulsed cell 
layers. Bars indicate 500µM. *p < 0.05 versus respective untreated controls. *p < 0.05 versus respective 
TGFβ1 (positive) myofibroblast controls. Data are represented as mean ± S.D, calculated from three 




Figure 39. In comparison with the myofibroblast controls, SAHA post-treatment reduced short-
term TGFβ1-effects in the multiple pulses model. SAHA exhibited limited effects on α-SMA expression 
but reduced collagen production. (a) Cell culture setup of a 2 x 4h TGFβ1 pulse on growth-arrested 
fibroblasts, administered over 2 consecutive days, followed by SAHA post-treatment for 24h. (b) 
Normalized densitometric SDS-PAGE analysis of the 24h collagen secretion rate by induced fibroblasts; 
(c) densitometric analysis of α-SMA normalized to β-actin expression; representative (d) SDS-PAGE; (e) 
immunoblots and (i) ICC pictures (α-SMA, red; phalloidin, green; DAPI, blue) of the 2 x 4h TGFβ1-pulsed 
cell layers. Bars indicate 500µM. *p < 0.05 versus respective untreated controls. *p < 0.05 versus 
respective TGFβ1 (positive) myofibroblast controls. Data are represented as mean ± S.D, calculated from 
three independent studies in triplicates, and expressed as -fold changes over respective controls. 
88 
 
4.3.3.3 SAHA pre- & post-treatment acted in synergy to normalize long-term TGFβ1 
effects 
From the independent results obtained with SAHA pre- and post-treatment, we proceeded to 
combine both SAHA pre- and post-treatment to assess if this combination had synergistic 
effects on TGFβ1-pulsed myofibroblast induction and maintenance. In comparison with the 
myofibroblast control cells, the administration of SAHA before and after a 4h TGFβ1 pulse was 
observed to abrogate collagen I production and reduced α-SMA expression at all assessed end-
points (Figure 40). When administered with double pulses, SAHA pre- and post-treatment 
normalized and reduced collagen production at days 1 and 7, respectively. However, α-SMA 





Figure 40. SAHA pre- and post-treatment normalized collagen I production and reduced α-SMA 
expression when administered with a 4h TGFβ1 pulse. (a) Cell culture setup of 24h SAHA treatment – 
4h TGFβ1 pulse – 24h SAHA post-treatment on growth-arrested fibroblasts. (b) Normalized densitometric 
SDS-PAGE analysis of the 24h collagen secretion rate by induced fibroblasts; (c) densitometric analysis 
of α-SMA normalized to β-actin expression; representative (d) SDS-PAGE; (e) immunoblots and (i) ICC 
pictures (α-SMA, red; phalloidin, green; DAPI, blue) of 4h TGFβ1-pulsed cell layers. Bars indicate 500µM. 
*p < 0.05 versus respective untreated controls. *p < 0.05 versus respective TGFβ1 (positive) 
myofibroblast controls. Data are represented as mean ± S.D, calculated from three independent studies in 




Figure 41. SAHA pre- and post-treatment normalized short-term TGFβ1-effects when administered 
with 2 x 4h TGFβ1 pulses. As compared to the myofibroblast control, SAHA treatment 
normalizedcollagen I production and reduced α-SMA expression 1 day post pulse. Collagen production 
but not α-SMA expression was reduced 7 days post-pulse. (a) Cell culture setup of 24h SAHA treatment – 
2 x 4h TGFβ1 pulse – 24h SAHA post-treatment on growth-arrested fibroblasts. (b) Normalized 
densitometric SDS-PAGE analysis of the 24h collagen secretion rate by induced fibroblasts; (c) 
densitometric analysis of α-SMA normalized to β-actin expression; representative (d) SDS-PAGE; (e) 
immunoblots and (i) ICC pictures (α-SMA, red; phalloidin, green; DAPI, blue) of the 2 x 4h TGFβ1-pulsed 
cell layers. Bars indicate 500µM. *p < 0.05 versus respective untreated controls. *p < 0.05 versus 
respective TGFβ1 (positive) myofibroblast controls. Data are represented as mean ± S.D, calculated from 
three independent studies in triplicates, and expressed as -fold changes over respective controls. 
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4.3.4 SAHA impeded myofibroblast motility 
To assess SAHA’s effects on myofibroblast motility, we employed the use of a wound healing 
assay on TGFβ1-treated myofibroblasts. Live phase contrast imaging demonstrated that SAHA 
impeded myofibroblasts migration (Figure 42). Using a linear best fit analysis to quantitate 
myofibroblast migration rates, we observed that myofibroblasts exhibited the fastest migration 
rate, while fibroblasts (regardless of SAHA treatment) migrated at a slightly slower rate. SAHA 
treated myofibroblasts was found to display the slowest migration rate (Figure 42c). 
 
Figure 42. SAHA impeded myofibroblast migration into the wound area. Fibroblasts were treated 
with and without TGFβ1 for 3 days. Cytokine containing media was removed and cultures treated with 
and without SAHA before removal of the ‘scratch’, and monitored for a further 3 days. (a) Representative 
phase contrast images (4x magnification) of cell migration into wound area; (b) quantitation of cell 
migration into wound area, evaluated by ImageJ at various time intervals after release. (c) Rate of 
migration was evaluated by plotting the linear best-fit curve to obtained data. *p < 0.05 versus respective 
untreated controls. Data are represented as mean ± S.D, calculated from three independent studies in 
triplicates, and expressed as -fold changes over respective controls. 
4.3.5 SAHA had no effect on myofibroblast contraction 
Another property of myofibroblast locomotion is contraction. Using an in vitro 3D polymerized 
collagen I gel to assess SAHA’s effects on TGFβ1-induced myofibroblast contractility, we 




Figure 43. SAHA had no effect on myofibroblast contraction. Fibroblasts in collagen gel lattices were 
treated with and without TGFβ1 for 2 days to allow for polymerization and stress formation within the 
lattice. Prior to contraction initiation, cytokine containing culture media was removed and replaced with or 
without SAHA. Quantitation of gel contraction was evaluated by measuring the gel diameter with a ruler at 
various times after release, over a span of 3 days. 10mM BDM (contraction inhibitor) was utilized for the 
assay negative control. Data are represented as mean ± S.D, calculated from three independent studies 







This chapter discusses the core findings of the project in rela tion to the memorized 
effects of TGFβ1 and SAHA’s anti -fibrotic effects when administered with TGFβ1 
pulses. 
. 
5.1 Development of a physiologically relevant in vitro fibrosis model 
In this study we considered the effects of pulsed TGFβ1 on WI-38 cells and made two 
significant observations. Firstly, a short TGFβ1 pulse had surprisingly long lasting effects as 
evidenced by the generation of a bona fide myofibroblast phenotype. This suggests some 
phenotypical signal retention mechanism or information storage in or around the cell. Secondly, 
this effect was transient; it wears off (Figure 44). We suggest here that the single pulse model 
comes closer to the actual physiological wound healing situation. Upon a TGFβ1 insult, affected 
fibroblasts differentiate into myofibroblasts to fulfill the functional requirement of ECM production 
and contraction; these cells subsequently undergo apoptosis in physiological healing [Rieder et 
al. 2007]. In a similar manner, collagen I production and α-SMA expression remain elevated 7 
days post-pulse and subsequently, production of collagen I and α-SMA was scaled down. 
Myofibroblast reversibility also occurs in liver fibrosis when the insult is removed [Dufour et al. 
1997]. Specifically for collagen synthesis, there exists a regulatory propeptide-mediated 
feedback on procollagen synthesis in human lung fibroblast cultures [Aycock et al. 1986, Wu et 
al. 1991], although it remains unknown if the decrease in collagen I expression observed is part 
of a negative feedback loop due to excessive collagen deposition on the ECM and not the 
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reversibility of phenotype. In the dermal wound healing model, the highest amount of active 
TGFβ1 release is between days 5-7 post-wounding, with a subsequent decrease thereafter 
[Yang et al. 1999], similar to the results shown in Figure 18.  
An additional pulse administered 24h later potentiated myofibroblast maintenance (Figure 20), 
and we suggest that this models a non-physiological in vivo wound healing situation. 
Pathological fibrotic conditions are characterized by the overproduction (and reduced 
remodeling) of ECM components and persistence of the myofibroblasts. Similarly, the multiple 
pulses model was characterized by elevated collagen I production and α-SMA expression 14 
days post-pulse. However, it remains unknown if the myofibroblast markers revert to baseline 
levels after the assessed 14 days period. 
 
Figure 44. Theoretical myofibroblast response to single and multiple TGFβ1 pulse(s). A single 
pulse of TGFβ1 modeled physiological wound repair, with myofibroblastic response increasing initially 
and decreasing after 7 days. Double TGFβ1 pulses extended this effect. 
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Comparing the newly developed in vitro models to traditional 4 days TGFβ1 treatment (Figure 
17), we demonstrated that the double pulses model (fibrotic condition) parallels the traditional 4 
days TGFβ1 treatment. This suggests that the current in vitro model, besides being a poor 
reflection of in vivo cytokine regulation, is insufficient as an in vitro model for physiological 
wound healing, but suffices as a platform for fibrotic pathologies. 
Pulsatile impact of cytokines (or TGFβ1) on target cells is not well studied, but it is conceivable 
that it offers advantages over continuous exposure. It avoids down-regulation of receptors on 
target cells as a possible response to signal bombardment [Hsieh et al. 1998]. While this keeps 
cells continuously responsive, it also reduces inertia in a feedback system. In contrast to 
hormones, growth factors work locally in a diffusion perimeter around releasing cells and can be 
stored and moved around in the ECM [Duchesne et al. 2012]. Release of TGFβ1 can be due to 
direct secretion (for example by inflammatory) cells or by proteolytic or mechanical release from 
matrix storage points, but it is not known whether these modes generate a continuous or a 
pulsatile-like scenario. In line with our findings, Webber et al. demonstrated that 72h treatment 
of TGFβ1 and removal thereafter induced a stable myofibroblast phenotype, mediated through 
SMAD3 phosphorylation, for up to 5 days in lung fibroblasts [Webber et al. 2009]. However, we 
establish that a short (0.5h) TGFβ1 pulse was sufficient for myofibroblast induction and 
maintenance, suggesting signal retention. TGFβ1 – TβRI/II interaction leads to phosphorylation 
of receptor activated SMADs (R-SMAD) SMAD2/3 and subsequent transcriptional regulation 
[Shi et al. 2003]. In a similar study focusing on TGFβ1/SMAD signaling dynamics, it was 
reported that cells have differing SMAD2-phosphoylation responses towards continuous and 
pulsatile TGFβ1 stimulation [Zi et al. 2011]. Further, we present novel evidence that trypsin 
passaging of myofibroblasts affected their phenotype (Figure 24). Trypsin, a serine protease, 
catalyzes the hydrolysis of peptide bonds [Rawlings et al. 1994], thereby releasing adherent 
cells off its surface, making it a useful tool in cellular sub-culture. Transformed cells are more 
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sensitive to trypsin [Brugmans et al. 1978], which provide an explanation as to why trypsin 
altered phenotypic properties in myofibroblasts but not fibroblasts. Trypsin also preferentially 
hydrolyses the main components of histone proteins (lysine and arginine residues), and 
trypsinzation of calf thymus cells was observed to release and hydrolyse histones, thereby 
compromising and disrupting nuclei structural integrity [Allfrey et al. 1962]. This suggests that 
trypsin passaging possibly altered histone properties in the passaged myofibroblasts. 
The mRNA expression levels of selected fibrotic genes (from microarray) were quantified 
(Figure 19, Figure 21) and results summarized in Table 8. 
Model Single Pulse – 0.5h, 4h Multiple Pulse – 2 x 0.5h, 2 x 4h 
Gene/Day 1 7 14 1 7 14 
ACTA2 
(α-SMA) 
 = =   = 
FZD8   =   = 
NOX4  = =   = 
TSPAN2   =    
Table 8. Gene expression levels of selected fibrotic genes in the single versus double pulse(s) 
model. Legend:  indicates a marked elevation in mRNA expression and  slightly elevated w.r.t 
untreated controls. 
ACTA2 (α-SMA): A single TGFβ1 pulse increased ACTA2 mRNA levels 24h post treatment, 
indicating elevated transcriptional activity, and post-translational conversion within a window of 
7 days to the protein form.  Multiple pulses extended this effect. ACTA2 expression reverted to 
baseline levels despite the persistence of protein expression, highlighting the variation between 
mRNA and actual protein levels, which casts light on mRNA levels solely taken as functional 
markers in experimental studies. 
FZD8: We firstly demonstrate that FZD8 was elevated 1 and 7 (slight) days post TGFβ1 pulses. 
Cultures were washed with HBSS to remove traces of exogenous TGFβ1, suggesting that there 
was an ongoing TGFβ1 loop as a reactive response to the pulse(s). TGFβ1 – TβRI/II interaction 
triggers a cascade of events which activates the canonical Wnt/β-catenin pathway required for 
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TGFβ1-mediated fibrogenesis in vitro and vivo [Akhmetshina et al. 2012]. In the mouse model, 
Wnt/β-catenin signaling promoteed increased synthesis of FN [Surendran et al. 2005], the 
progression of chronic renal injury [Surendran et al. 2005] and renal interstitial fibrosis [He et al. 
2009].  
NOX4: In vivo studies showed that NOX4 inhibition exhibited curative effects [Laleu et al. 2010]. 
Also, knockdown of NOX4 in the bleomycin mouse model abrogated lung fibrosis [Hecker et al. 
2010]. NOX4 was expressed in thickened pulmonary arteries of IPF patients [Pache et al. 2011] 
and was observed to be responsible for generation of ROS in injured cardiac tissue [Kuroda et 
al. 2010], thereby correlating its relationship in both cardiac and pulmonary fibrosis. NOX4 was 
also a mediator in hepatic fibrosis [Paik et al. 2011]. In the model, increased NOX4 expression 
suggests the probable production of ROS as part of a first-phase response to TGFβ1 pulse(s). 
Downregulation at days 7 and 14 post-pulse suggest that ROS was no longer present after a 
single TGFβ1 pulse. We propose that an additional TGFβ1 pulse prolonged ROS production. 
TSPAN2: Presenting a general overview, in airway diseases (such as CF), TSPAN24/CD151 
was observed to be an identification marker indicating the capacity of human adult basal cells 
for restoration of functional airway epithelial [Hajj et al. 2007]. TSPAN26/CD37 induced 
inflammation and knockdown of TSPAN26 attenuated glomerular IgA nephropathy [Rops et al. 
2010]. TSPAN2 has not been implicated in fibrosis and we show for the first time, elevated 
TSPAN2 mRNA levels, concomitant to increased collagen I production, in response to TGFβ1 
pulse(s). 
5.2 Investigating the memorized effects of TGFβ1 pulses 
In this section, we investigated three mechanisms – autocrine TGFβ1 production, epigenetic 
changes and cell – ECM influence to explain the memorized effects of TGFβ1 pulses. Firstly 
investigating autocrine TGFβ1 production, we noticed with great interest that a single pulse of 
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exogenous TGFβ1 led to the subsequent release of endogenous active TGFβ1 and therefore to 
an autocrine stimulation that was dampened during the first 24 hours (Figure 22a – b). Although 
we observe elevated latent TGFβ1 production after TGFβ1 pulses (Figure 22c – d), it remains 
unclear if the cells activate latent TGFβ1 storage. Wipff et al. demonstrated that latent TGFβ1 
was stored in the ECM and myofibroblasts deposited and activated latent TGFβ1 stores in a 
contractile dependent manner [Wipff et al. 2008], and we propose that a latent TGFβ1 activation 
loop, mediated by myofibroblast contraction may contribute to the maintenance of phenotype 
after TGFβ1 pulse(s).  
SAHA hyperacetylated histone-3 [Wang et al. 2009] leading to the speculation that acetylation 
changes mediated gene transcription after TGFβ1 treatment. Therefore, at the next level of 
intracellular changes that transiently stabilise the myofibroblast phenotype after a single TGFβ1 
pulse; we considered epigenetic modifications affecting histone acetylation and DNA 
methylation. We could not establish significant changes of histone acetylation (Figure 23), and a 
CpG methylation scan of the proximal promoter regions of selected TGFβ1-responsive genes 
(ACTA and COL1A1, Table 7) was inconclusive, likely because these genes are downstream 
effector genes of TGFβ1 treatment. While this does not rule out methylation changes in other 
genes and regions under TGFβ1, this appears to fit the transient nature of the phenotypic 
change we have observed. 
As the next option, we considered microenvironmental changes based on the notion of matrix 
reciprocity [Bisell et al. 1982, Sage et al. 1982]. We observed that the memorized TGFβ1 effects 
were a result of ECM influences (Figure 26). SDS-PAGE analysis of collagen deposition on 
decellularised ECM revealed minimal collagen I deposition (Figure 25c – d), likely due to the 
short culture period. However, ICC results suggested that the amount of collagen I deposited 
sufficed as a platform to assess the ECM’s influence on untreated fibroblasts. TGFβ1 pulses 
elevated collagen I and FN deposition (Figure 25e – f), and of strong relevance to our 
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observations, the FN ED-A (splice variant) domain was observed to be crucial for TGFβ1 
dependent myofibroblast induction in primary fibroblasts [Serini et al. 1998]. FN also colocalized 
with integrins, a mediator of contraction in fibrosis [Schultz et al. 2011, Wipff et al. 2008]. Taken 
together, the collagen I and FN network may functionally mediate phenotype changes in the 
untreated fibroblasts, probably through an array of bio- and/or mechanochemical stimulus 
[Rieder et al. 2007, Kis et al. 2011]. We observed with great interest that the M1 ECM 
(compared to M7) was better able to induce myofibroblast differentiation. We propose that this 
could be attributed to a variety of reasons: a) elevated LTBP-1 expression in M1 ECM (Figure 
27a, discussed below); b) ECM remodeling, mediated by MMPs and proteases over the 7 day 
period, thereby reducing ‘myofibroblast inductive’ molecules required for differentiation; 3) 
production of other profibrogenic cytokines (e.g. CTGF, PDGF) [Widgerow et al. 2011]; and 4) 
the rapid kinetics of SMAD assembly, nuclear accumulation and subsequent activation of 
transcription of fibrogenic genes. TGFβ1 – TβRI/II leads to SMAD signaling processes and the 
formation of heteromeric complex SMAD2/3 – 4 which is translocated to the nucleus [Heldin et 
al. 1997]. Recently, it had been shown that the formation of heteromeric complex and nuclear 
translocation of SMAD2/3 – 4 takes place within 20 mins [Zieba et al. 2012]. An additional 
TGFβ1 pulse was observed to increase the expression of classic myofibroblast markers. 
Increasing TGFβ1 concentrations has been shown to be directly proportional to SMAD 
phosphorylation [Webber et al. 2009, Zi et al. 2011], and we suggest that this was a result of 
elevated on-going TGFβ1 signaling and transcriptional processes. The ECM control was 
observed to exhibit reduced α-SMA and collagen I expression as compared to TCP control and 
this may be attributed to a collagen I feedback mechanism which acts to downregulate and/or 
suppress basal collagen I through propeptide-mediated feedback regulatory role on procollagen 
synthesis and α-SMA expression in the re-seeded fibroblasts [Aycock et al. 1986, Wu et al. 
1991]. In line with our findings, studies by other groups have reported ECM-dependent 
myofibroblast differentiation. Vitronectin mediated corneal myofibroblast differentiation [Wang et 
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al. 2012], collagen type VI induced myofibroblast differentiation in cardiac fibroblasts [Naugle et 
al. 2006] and ECM accumulation increased the development of dermal fibroblasts [Distler et al 
2007].  
LTBP-1 interacted directly with TGFβ1 [Saharinen et al. 2000] and was elevated in M1 ECM 
(Figure 27a), suggesting LTBP-1-mediated myofibroblast activation. In relation to our findings, 
LTBP-1 was observed to modulate the bioactivity of TGFβ1 [Mangasser-Stephan et al. 2001], 
and was upregulated in IPFs [Khalil et al. 2001]. In vivo, LTBP-1 knockout mice displayed 
increased resistance to hepatic fibrogenesis [Drews et al. 2008], suggesting that LTBP-1 direct 
association with TGFβ1 bioactivity. Double immunofluorescence staining reported the co-
localization of LTBP-1 with FN and collagen I [Mangasser-Stephan et al. 2001]. It is not known 
whether LTBP-1 co-localizes with collagen I and FN our system, but the coincidental elevated 
collagen I, FN and LTBP-1 deposition observed suggests that collagen I and FN have in part, a 
role to play in the LTBP-1 regulation of the myofibroblast phenotype. A schematic depicting the 
proposed ECM-dependent latent TGFβ1 release and activation is illustrated in Figure 27b. It has 
been previously shown that the myofibroblast ECM contained self-generated TGFβ1 stores and 
activated latent TGFβ1 storage in a contractile dependent manner [Wipff et al. 2007, 2008]. 
Similarly, we propose that the release of latent TGFβ1 was mediated by contractile 
myofibroblasts which were more efficient in utilizing the self-generated TGFβ1 stores available 
on the M1 TGFβ1-pulsed ECM.  
In a crossover experiment, we show that the normal fibroblast ECM reduced myofibroblast 
marker expression in normal and pathological myofibroblasts. Normal fibroblast ECM reduced to 
or reduced below fibroblast levels, collagen I production in re-seeded WI-38 (Figure 31) and 
HSF (Figure 32) myofibroblasts respectively, suggesting that the ECM contained soluble factors 
which regulated collagen production – a classic case where cues from the ECM modulated cell 
phenotype [Bisell et al. 1982, Widgerow et al. 2010, Schultz et al. 2011]. We suggest that 
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integrin-mediated cell attachment to collagens mediated increased MMP production [Steffensen 
et al. 2001] and ECM degradation, mechanisms which interfered with collagen suppression. 
Also, feedback from ECM components (e.g. collagen IV, proteoglycans) may act in synergy to 
blunt collagen production. In relation to our findings, the myofibroblast phenotype was reversed 
when myofibroblasts were cultured on Matrigel [Sohara et al. 2002] and cyropreserved amniotic 
membrane stromal surfaces [Li et al. 2008]. α-SMA expression however, remained unchanged 
in comparison to myofibroblasts, suggesting that ECM factors were unable to fully reverse the 
myofibroblast phenotype. Xie et al. demonstrated that HSFs exhibited higher endogenous 
SMAD2, along with lower inhibitory SMAD7 levels [Xie et al 2008], increased sensitivity to 
TGFβ1 [Chen et al. 2002] and produced CTGF [Colwell et al. 2005], suggesting that an on-
going TGFβ1 – SMAD2/3 signaling loop probably perpetuated the maintenance of α-SMA 
expression. Also, we propose that fibroblast ECM components (collagen I and FN) maintained 
α-SMA expression in the re-seeded myofibroblasts. Substantiating our proposition, collagen I [Li 
et al. 2008] and FN ED-A [Serini et al. 1998] mediated myofibroblast maintenance. HSFs also 
exhibited increased FN deposition [Kischer et al. 1983] suggesting that FN (ED-A domain) plays 
a role in myofibroblast maintenance. Myofibroblast contraction may also activate basal latent 
TGFβ1 stores [Wipff et al. 2008], contributing to phenotypic maintenance. The normal fibroblast 
ECM however, appeared to have no effect on IPFs (Figure 33). IPFs endogenously expressed 
high levels of COL1A1 and TGFβ1 mRNA [Ramos et al. 2001] and NOX4 [Amara et al. 2010]; 
NOX4 being a crucial factor in TGFβ1-induced myofibroblast activation and fibrogenic response 
[Amara et al. 2010, Hecker et al. 2009, Bocchino M et al. 2010], suggesting that elevated 
endogenous NOX4 and TGFβ1 levels contributed to phenotypic maintenance.  There has been 
limited reports of SMAD regulation in IPFs but we cannot rule out that TGFβ1 stimulation may 
have resulted in an NOX4 mediated autocrine positive loop of TGFβ1 signaling and production. 
Also IPF myofibroblasts could possibly remodel the ECM, contributing to phenotypic 
maintenance. Reduced α-SMA expression in the ECM negative control was observed, similar to 
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the ECM control in Figure 26, suggesting that this was a result of the fibroblast ECM feedback 
mechanism interfering with α-SMA transcriptional regulation. HSF myofibroblasts cultured on 
ECM and further stimulated with TGFβ1 (ECM positive control in Figure 32) expressed reduced 
collagen I production suggesting that exogenous TGFβ1 was not able to over-ride signals from 
the ECM. It is not known if collagen I feedback from the ECM may play a regulatory role on 
procollagen synthesis in the re-seeded myofibroblasts [Aycock et al. 1986, Wu et al. 1991].  
Taken together, it appears that without appropriate cues from the ECM, myofibroblasts aim to 
remodel a normal ECM, making it fibrotic in nature (e.g. IPFs). With the HSF and WI-38 
myofibroblasts however, the normal fibroblast ECM-mediated cues blunted collagen production, 
leading to reduced ECM accumulation. 
5.3 Revisiting SAHA’s anti-fibrotic potential 
SAHA was non-toxic to fibroblasts, consistent with the findings of other groups [Wang et al. 
2009, Cho et al. 2012]. The effector caspase-3/7 plays an essential role in the signal 
transduction of apoptotic cues and was elevated 1 day post-SAHA treatment (Figure 35), 
suggesting that SAHA increased caspase-dependent sensitivity of myofibroblasts to apoptotic 
signals. In agreement with our findings, HDACi TSA induced apoptosis in pathological keloid 
fibroblasts [Diao et al. 2011]. Caspase activity is an early marker along the apoptotic pathway 
and the decreased caspase-3/7 activity observed at days 2 – 3 after SAHA treatment does not 
rule out other mechanistic events along the apoptotic pathway (e.g. DNA fragmentation) which 
could be taking place concurrently. 
Revisiting SAHA’s effects in conjunction with TGFβ1 pulse(s), SAHA anti-fibrotic effects were 




Model 4h TGFβ1 pulse 2 x 4h TGFβ1 pulse 
Day Day 1 Day 7 Day 1 Day 7 
Marker Col I α-SMA Col I α-SMA Col I α-SMA Col I α-SMA 
Pre-treat = = ― ― ― ― ― ― 
Post-treat = ↓ ↓ ― ↓ ↓ ↓ ― 
Pre- & 
post-treat 
= ↓ = ↓ = ↓ ↓ ― 
Table 9. Summary of SAHA treatment versus TGFβ1 pulse(s). Pre- and post- SAHA treatment 
exhibied the most significant effects in reducing collagen I production and α-SMA expression. Legend: ↓ 
indicates a reduction in marker expression; ― indicates no effect; and = represents normalization of 
expression w.r.t TGFβ1 positive myofibroblast control.  
When administered in conjunction with TGFβ1 pulses, SAHA possessed anti-fibrotic potential. 
SAHA exhibited the highest anti-fibrotic potential 1 day post-SAHA treatment and it appeared 
that the duration of SAHA treatment correlated to anti-fibrotic effects, suggesting: 1) SAHA’s 
reversible effects; and 2) the interference of SAHA with TGFβ1 signaling.  
1) SAHA’s effects were reversible 
We demonstrated SAHA’s reversible effects (Figure 45), suggesting that SAHA was no longer 
able to exert anti-fibrotic effects when removed from culture media. Confirming our findings, the 
reversible effects of HDACi LBH589 action was previously reported [Beckers et al. 2007]. 
SAHA’s reversibility also suggests that the use of SAHA minimizes spill-over effects after 






Figure 45. Reversible effects of SAHA-induced hyperacetylation on α-tubulin and histone 3. 
Fibroblasts were treated with and without SAHA for 48h. Cultures were assessed (a) immediately; and (b) 
48h post-SAHA removal.  Fibroblasts were maintained in 0.5% FBS DMEM post-SAHA removal. 
2) Interference of SAHA with TGFβ1 signaling: SMAD-dependent and independent mechanisms 
We propose that SAHA interfered with the TGFβ1 signaling process by: 1) competing or 
interfering with SMAD regulation and activation; 2) stabilizing SMAD7 inhibitory action; and 3) 
interfering through 5’-TG-3’-interacting factor (TGIF) homeoproteins. Supporting our proposition, 
the literature has demonstrated the relationship between HDAC and SMADs. 1) HDACi TSA 
inhibited nuclear translocation and DNA binding of SMAD3/4 complex in SSc fibroblasts [Huber 
et al. 2007]; and inhibited TGFβ1-induced SMAD2/3 [Cho et al. 2012]. 2) TSA rescued TGFβ1-
suppressed SMAD7 signaling [Cho et al. 2012]. Authors also reported that HDAC1-mediates 
SMAD7 deacetylation and decreased its stability [Simonsson et al. 2005]. Therefore, SAHA may 
hyperacetylate and stabilize SMAD7, but further work is required to elucidate this. 3) TGIF-1 
and -2 are two endogenous repressors of the TGFβ1 signaling pathway. siRNA specific 
downregulation of HDAC4 stimulated the expression of TGIFs [Glenisson et al. 2007], 
demonstrating the relationship between HDACs and TGIFs. Also, TSA affected TGFβ1-
mediated SMAD signaling and strongly induced the expression of TGIFs [Rombouts et al. 2004]. 
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HDACi also has been shown to interfere with transcriptional regulation in a SMAD-independent 
manner. TSA neither altered SMAD expression nor activation, but instead suppressed TGFβ1-
induced expression of Sp1, an essential transcription factor for SMAD-dependent collagen 
synthesis [Ghosh et al. 2007]. In the presence of TGFβ1, TSA abrogated the induction of cell-
cell and cell-ECM modulators, disintegrin and metalloproteinase 12 (ADAM12) and TIMP1 
genes, without affecting SMAD phosphorylation [Barter et al. 2010]. Taken together, 
independent studies suggested that SAHA may affect TGFβ1-induced myofibroblast 
differentiation in a SMAD-dependent and -independent manner. 
Our results are also aligned with current literature of HDACi and collagen production. Valproic 
acid decreased collagen-induced arthritis disease severity by decreasing collagen production 
[Saouaf et al. 2009]. HDACi sodium valproate and phenylbutyrate inhibited collagen I mRNA 
and protein expression in HSCs [Rishikof et al. 2004, Wantanabe et al. 2011]. TSA normalized 
TGFβ1-induced collagen synthesis in skin [Ghosh et al. 2007], keloid [Diao et al. 2011] and SSc 
fibroblasts [Wang et al. 2006]. Therefore, we speculate that SAHA treatment in conjunction with 
TGFβ1 pulse(s) interfered with downstream mediators of the collagen I biosynthesis pathway. In 
summary, the current literature supports the hypothesis that HDACi SAHA reduced 
myofibroblast marker expression by: 1) competing or interfering with SMAD regulation and 
activation, 2) functioning as a transcriptional co-repressor in the TGFβ1 transcriptional axis and 
3) increasing the stability of inhibitory SMAD7. 
Exploring another facet of myofibroblast locomotion, we have demonstrated that SAHA 
compromised myofibroblast migration (Figure 42), suggesting the inhibition of HDAC6 (Class 
IIb), an essential HDAC required for cellular motility [Tran et al. 2007]. Also, it has been 
previously established that the presence of α-SMA was a signal for retardation of migratory 
behavior in myofibroblasts [Rønnov-Jessen et al. 1996]. SAHA reduced or normalised α-SMA 
expression in comparison to the myofibroblast controls, and this could explain migratory 
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retardation in SAHA-treated myofibroblasts. SAHA however, had no effect on myofibroblast 
contractility (Figure 43). Interestingly, it was recently shown that HDAC8 (Class I) associated 
with α-SMA to regulate cell contractility [Waltregny et al. 2005]. Our findings suggest the 
preferential inhibition of HDAC6. Indeed, SAHA, a non-selective HDACi for Class I/II HDACs, 
exhibited higher binding affinity to HDAC6 [Estiu e al. 2008, Wang et al. 2011], and significantly 
weaker (≈100x less) inhibition of HDAC8 [Estiu et al. 2008, Khan et al. 2008], a result of 
evolutionary divergence and differential structural characteristics between HDAC6 and HDAC8 




Conclusions and Future Work 
This chapter presents the overall conclusions of the project and discusses future work options 
for scientific advancement in the field of peri-implant fibrosis. 
 
6.1 Conclusion 
Fibroproliferative diseases and fibrosis around organs and implants continue to pose a 
substantial disease burden today and a therapeutic solution is keenly sought. Central to the 
progression of fibrosis are the myofibroblasts. There remains an unmet need for an effective 
anti-fibrotic therapeutic agent that can reverse or blunt the progression of fibrosis. In an 
indication discovery approach, our group has previously established the anti-fibrotic potential of 
FDA-approved HDACi, SAHA [Wang et al. 2009]. However, SAHA was unable to abrogate 
TGFβ1-effects if cultures were exposed to TGFβ1 treatment 24h before SAHA treatment. 
1) To better assess the anti-fibrotic potential of SAHA, we developed a patho-physiologically 
relevant model to recapitulate pulsatile in vivo cytokine regulation on an in vitro platform. We 
demonstrated that a single 0.5h TGFβ1 pulse had long-term effects on the myofibroblast 
phenotype, and that this effect can be potentiated by a second pulse one day later. Further, we 
described the regulation and trend of selected fibrogenic genes in response to TGFβ1 pulse(s). 
We believe that our current model is a more realistic reflection of in vitro wound healing. It will 
form the basis for future anti-fibrotic therapy screening, and should contribute to the current 
knowledge of TGFβ1 and the understanding of myofibroblast induction and maintenance.  
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2) Intrigued by the long-lasting changes observed with a TGFβ1 pulse(s), we assessed 
mechanistic events which may contribute towards the myofibroblast phenotype maintenance. 
Although we did not observe epigenetic changes, we observed that the memorized effects of 
TGFβ1 were based on cell-matrix reciprocity: the microenvironment appears to retain a memory 
of TGFβ1 insults in the form of biochemical cues, including higher levels of endogenous LTBP-1 
deposition on the ECM. This suggests that a positive feed-back loop was established and 
should in turn, lead to the perpetuation of the myofibroblast phenotype after limited TGFβ1 
treatment. However, this was not the case and we observed instead the dampening and erasure 
of myofibroblast induction signals possibly due to matrix turnover and remodeling. In the 
crossover experiment, we demonstrated that the normal fibroblast ECM was able to normalize 
or reduce to fibroblast levels, collagen I production in WI-38 and HSF myofibroblasts, but not 
IPF fibroblasts. This suggests that biochemical cues from normal fibroblast ECM were able to 
remove cues for elevated collagen I production in the myofibroblasts. Together, the study on 
cell-ECM reciprocity has bearing for the development of antifibrotic therapy and points to future 
research avenues to study fibrotic processes. 
3) Revisiting SAHA’s effects in conjunction with TGFβ1 pulse(s), we demonstrated the reduction 
of classic myofibroblast markers in comparison with the myofibroblasts controls. This study 
provided valuable insight by reconfirming SAHA’s anti-fibrotic potential in a physiologically 
relevant setting. Targeting another dimension of anti-fibrotic therapy, we presented evidence of 
compromised myofibroblast motility but not contractility.  
Our findings contribute towards the understanding of TGFβ1-mediated myofibroblast induction 
and maintenance and the use of SAHA to curb fibrosis. SAHA is currently in clinical use for T-
cell lymphoma treatment and data derived from this study, and subsequent in vivo studies can 
be faster translated towards clinical treatment of peri-implant fibrosis.  
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6.2 Future Work 
a) The fibroblast ECM mode of action is still unknown and mass spectrometry analysis of 
soluble fractions in the ECM may unravel certain targets which may form or assist in anti-fibrotic 
therapy. The ECM can further be used as a platform to assess the anti-fibrotic potential in other 
cell lines. Incorporation of the decellularized ECM with anti-fibrotic agents and employed as a 
platform to assess drug efficacy in a native system will also serve as a feasible option for future 
exploration. 
b) SAHA’s mode of action in anti-fibrosis still continues to elude us and it would be interesting to 
single out independent or group of enzymes which are responsible for SAHA’s effects, and the 
point at which SAHA interferes with TGFβ1 signaling. Also, SAHA could be incorporated into 
decellularized fibroblasts ECM and this study will potentially lay foundation for drug-mediated 
ECM treatment.  
c) This thesis provides further promising evidence of SAHA’s anti-fibrotic effects, and the next 
stage would be to move into studying SAHA’s effects in a preclinical animal model. We have 
designed a peri-implant model which will involve a pilot and exploratory study. Briefly, 
commercial 0.22µM filtered ovalbumin (Sigma-Aldrich, St. Louis, MO) and/or drug of interest, 
SAHA will be loaded into the ALZET® (Durect Corporations, Cupertino, CA) osmotic pump. The 
pump will be subcutaneously implanted on the dorsal surface of the mouse.  
Pilot study: The ALZET® pump will provide continuous infusion of commercial grade ovalbumin 
to site of interest. Animals will be sacrificed every fortnight, with the last experimental endpoint 2 
months post-implant to study onset of fibrosis. Histopathological studies (staining of collagen I 




Exploratory Study: To assess SAHA efficacy in preventing the occurrence of peri-implant 
fibrosis, the ALZET® pump will provide continuous infusion of ovalbumin and SAHA to the 
targeted region. After 3 – 4 weeks post-implant (using onset of fibrosis data obtained from pilot 
study), the animals will be sacrificed. To assess the efficacy of SAHA in curbing or reducing 
fibrosis after it has been established, the animals will first undergo a surgery for ovalbumin 
infusion. Upon the onset of fibrosis, the ovalbumin-filled pump will be removed and a new 
SAHA-filled pump will be implanted in place of the old pump. Histopathological studies, 
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TERMIS, Asia-Pacific Chapter, Singapore: Poster Presentation (2011) 
Biomedical Engineering Society: Oral Presentation (2010) 
TERMIS, Europe Chapter, Ireland: Poster Presentation (2009) 
East-Asian Pacific Student Workshop: Oral Presentation (2009) 
Appendix I.B Awards 
TERMIS, Asia-Pacific Chapter: SYIS Young Investigator Best Poster Presentation 
Award, 1st Runner-Up (2011) 
Biomedical Engineering Society, 5th Meeting: Best Oral Presenter Award, 1st Runner-Up 
(2010) 
East-Asian Pacific Student Workshop, 3rd Meeting: Top 10 Best Oral Presenter Award 
(2009) 
 
